

**Gerald Bronfman Department of Oncology Annual Report 2017  
Publications**

**Bassam Abdulkarim**

1. Chaddad A, Desrosiers C, Toews M, **Abdulkarim B**. Predicting survival time of lung cancer patients using radiomic analysis. *Oncotarget*. 2017 Nov 1;8(61):104393-104407. doi: 10.18632/oncotarget.22251. eCollection 2017 Nov 28.
2. Kaur S, Ramdzan ZM, Guiot MC, Li L, Leduy L, Ramotar D, Sabri S, **Abdulkarim B**, Nepveu A. CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide. *Neuro Oncol*. 2017 Sep 26. doi: 10.1093/neuonc/nox178. [Epub ahead of print]
3. Garnier D, Meehan B, Kislinger T, Daniel P, Sinha A, **Abdulkarim B**, Nakano I, Rak J. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. *Neuro Oncol*. 2017 Jul 28. doi: 10.1093/neuonc/nox142. [Epub ahead of print]
4. Chatterjee A, Serban M, **Abdulkarim B**, Panet-Raymond V, Souhami L, Shenouda G, Sabri S, Jean-Claude B, Seuntjens J. Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site. *Int J Radiat Oncol Biol Phys*. 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.
5. Gupta N, Jung K, Wu C, Alshareef A, Alqahtani H, Damaraju S, Mackey JR, Ghosh S, Sabri S, **Abdulkarim BS**, Bigras G, Lai R. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer. *Oncotarget*. 2017 Apr 25;8(17):28101-28115. doi: 10.18632/oncotarget.15891.
6. Azoulay M, Santos F, Shenouda G, Petrecca K, Oweida A, Guiot MC, Owen S, Panet-Raymond V, Souhami L, **Abdulkarim BS**. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution. *J Neurooncol*. 2017 May;132(3):419-426. doi: 10.1007/s11060-017-2383-2. Epub 2017 Apr 3.
7. Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot MC, Corredor AG, **Abdulkarim B**. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. *Int J Radiat Oncol Biol Phys*. 2017 Mar 1;97(3):487-494. doi: 10.1016/j.ijrobp.2016.11.006. Epub 2016 Nov 15.

**Jason Agulnik**

1. Kasymjanova G, Small D, Cohen V, Jagoe RT, Batist G, Sateren W, Ernst P, Pepe C, Sakr L, **Agulnik J**. Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes. *Curr Oncol*. 2017 Oct;24(5):302-309. doi: 10.3747/co.24.3611. Epub 2017 Oct 25.

**Moulay Alaoui-Jamali**

1. Rodrigues PC, Sawazaki-Calone I, Ervolino de Oliveira C, Soares Macedo CC, Dourado MR, Cervigne NK, Miguel MC, Ferreira do Carmo A, Lambert DW, Graner E, Daniela da Silva S, **Alaoui-Jamali MA**, Paes Leme AF, Salo TA, Coletta RD. Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. *Oncotarget*. 2017 Aug 19;8(43):74736-74754. doi: 10.18632/oncotarget.20360. eCollection 2017 Sep 26.

- Zhan Y, Guo J, Yang W, Goncalves C, Rzymiski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. *J Clin Invest*. 2017 Nov 1;127(11):4179-4192. doi: 10.1172/JCI91258. Epub 2017 Oct 16.
- Lubov J, Maschietto M, Ibrahim I, Mlynarek A, Hier M, Kowalski LP, **Alaoui-Jamali MA**, da Silva SD. Meta-analysis of microRNAs expression in head and neck cancer: uncovering association with outcome and mechanisms. *Oncotarget*. 2017 Jul 13;8(33):55511-55524. doi: 10.18632/oncotarget.19224. eCollection 2017 Aug 15.
- Bijian K, Kaldre D, Wang TT, Su J, Bouttier M, Boucher A, **Alaoui-Jamali M**, White JH, Gleason JL. Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. *J Steroid Biochem Mol Biol*. 2017 Aug 25. pii: S0960-0760(17)30225-X. doi: 10.1016/j.jsbmb.2017.08.010. [Epub ahead of print]
- Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, Richard S, **Alaoui-Jamali M**, Orthwein A, McCaffrey L, Witcher M. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. *Sci Adv*. 2017 May 24;3(5):e1601898. doi: 10.1126/sciadv.1601898. eCollection 2017 May.
- Chang CH, Bijian K, Qiu D, Su J, Saad A, Dahabieh MS, Miller WH Jr, **Alaoui-Jamali MA**. Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells. *Oncotarget*. 2017 May 9;8(19):31199-31214. doi: 10.18632/oncotarget.16105.
- Kahouli I, Malhotra M, Westfall S, **Alaoui-Jamali MA**, Prakash S. Design and validation of an orally administered active *L. fermentum*-*L. acidophilus* probiotic formulation using colorectal cancer *Apc Min/+* mouse model. *Appl Microbiol Biotechnol*. 2017 Mar;101(5):1999-2019. doi: 10.1007/s00253-016-7885-x. Epub 2016 Nov 11.

### **Thierry Alcindor**

- Gorelik N, Reddy SMV, Turcotte RE, Goulding K, Jung S, **Alcindor T**, Powell TI. Early detection of metastases using whole-body MRI for initial staging and routine follow-up of myxoid liposarcoma. *Skeletal Radiol*. 2017 Dec 23. doi: 10.1007/s00256-017-2845-9. [Epub ahead of print]
- Chan E, Chiorean EG, O'Dwyer PJ, Gabrail NY, **Alcindor T**, Potvin D, Chao R, Hurwitz H. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. *Cancer Chemother Pharmacol*. 2017 Dec 13. doi: 10.1007/s00280-017-3494-3. [Epub ahead of print]
- Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, **Alcindor T**, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. *J Clin Oncol*. 2017 Oct 20;35(30):3433-3439. doi: 10.1200/JCO.2016.71.6605. Epub 2017 Aug 30.
- Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, **Alcindor T**, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. Doxorubicin plus

evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017

### Armen Aprikian

1. Dragomir A, **Aprikian A**, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S. Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. *CMAJ Open.* 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005.
2. Bramhecha YM, Guérard KP, Rouzbeh S, Scarlata E, Brimo F, Chevalier S, Hamel L, Dragomir A, **Aprikian AG**, Lapointe J. Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention. *Mol Cancer Res.* 2018 Jan;16(1):115-123. doi: 10.1158/1541-7786.MCR-17-0270. Epub 2017 Oct 9.
3. Hu J, **Aprikian AG**, Cury FL, Vanhuyse M, Zakaria AS, Richard PO, Perreault S, Dragomir A. Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer. *Clin Genitourin Cancer.* 2017 Sep 5. pii: S1558-7673(17)30266-5. doi: 10.1016/j.clgc.2017.08.011. [Epub ahead of print]
4. Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, **Aprikian AG**, Lapointe J, Chevalier S, Giguère V. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. *Genes Dev.* 2017 Jul 19. doi: 10.1101/gad.299958.117. [Epub ahead of print]
5. Traboulsi SL, Brimo F, Yang Y, Maedler C, Prévost N, Tanguay S, **Aprikian AG**, Kassouf W. Pathology review impacts clinical management of patients with T1-T2 bladder cancer. *Can Urol Assoc J.* 2017 Jun;11(6):188-193. doi: 10.5489/cuaj.4126.
6. Bachir BG, Souhami L, Mansure JJ, Cury F, Vanhuyse M, Brimo F, **Aprikian AG**, Tanguay S, Sturgeon J, Kassouf W. Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. *Bladder Cancer.* 2017 Apr 27;3(2):105-112. doi: 10.3233/BLC-160090.
7. Zakaria AS, Santos F, Dragomir A, Kassouf W, Tanguay S, **Aprikian A**. Health care services utilization during the last 6 months of life among patients with bladder cancer who underwent radical cystectomy in Quebec, Canada. *Urol Oncol.* 2017 Sep;35(9):539.e1-539.e7. doi: 10.1016/j.urolonc.2017.04.005. Epub 2017 May 4.
8. Rocha J, **Aprikian AG**, Vanhuyse M, Cury FL, Hu J, Prévost N, Dragomir A. Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. *CMAJ Open.* 2017 Mar 28;5(1):E265-E272. doi: 10.9778/cmajo.20160082. eCollection 2017 Jan-Mar.
9. Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, **Aprikian A**, Chevalier S, Thomson AA. Asporin is a stromally expressed marker associated with prostate cancer progression. *Br J Cancer.* 2017 Mar 14;116(6):775-784. doi: 10.1038/bjc.2017.15. Epub 2017 Feb 2.
10. Khare SR, **Aprikian A**, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A,

Sridhar SS, Traboulsi SL, Kassouf W. Quality indicators in the management of bladder cancer: A modified Delphi study. *Urol Oncol*. 2017 Jun;35(6):328-334. doi: 10.1016/j.urolonc.2016.12.003. Epub 2017 Jan 3.

11. Khosrow-Khavar F, Rej S, Yin H, **Aprikian A**, Azoulay L. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. *J Clin Oncol*. 2017 Jan 10;35(2):201-207. Epub 2016 Nov 21.

#### **Jamil Asselah**

1. Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, **Asselah J**, Meterissian S, Guiot MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. *Cell Rep*. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
2. Mandilaras V, Bouganim N, Yin H, **Asselah J**, Azoulay L. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. *Br J Cancer*. 2017 Jan 3;116(1):103-108. doi: 10.1038/bjc.2016.375. Epub 2016 Nov 15.

#### **Laurent Azoulay**

1. Abrahami D, Yin H, Yu OHY, Pollak MN, **Azoulay L**. Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes. *Epidemiology*. 2017 Dec 26. doi: 10.1097/EDE.0000000000000793. [Epub ahead of print]
2. Loo SY, Chen BY, Yu OHY, **Azoulay L**, Renoux C. Testosterone replacement therapy and the risk of stroke in men: A systematic review. *Maturitas*. 2017 Dec;106:31-37. doi: 10.1016/j.maturitas.2017.08.013. Epub 2017 Sep 1. Review.
3. Yu O, **Azoulay L**, Yin H, Filion KB, Suissa S. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. *Am J Med*. 2017 Oct 12. pii: S0002-9343(17)31030-6. doi: 10.1016/j.amjmed.2017.09.044. [Epub ahead of print]
4. Wu JW, **Azoulay L**, Majdan A, Boivin JF, Pollak M, Suissa S. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. *J Clin Oncol*. 2017 Nov 10;35(32):3647-3653. doi: 10.1200/JCO.2017.73.4491. Epub 2017 Sep 27.
5. Douros A, Yin H, Yu OHY, Filion KB, **Azoulay L**, Suissa S. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. *Diabetes Care*. 2017 Nov;40(11):1506-1513. doi: 10.2337/dc17-0595. Epub 2017 Sep 1.
6. Davidson MA, Mattison DR, **Azoulay L**, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. *Crit Rev Toxicol*. 2017 Aug 17:1-57. doi: 10.1080/10408444.2017.1351420. [Epub ahead of print]
7. Hicks BM, Klil-Drori AJ, Yin H, Campeau L, **Azoulay L**. Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer. *Epidemiology*. 2017 Sep;28(5):712-718. doi: 10.1097/EDE.0000000000000678.
8. Taussky D, Soulières D, **Azoulay L**, Yin H, Bahig H, Bahary JP, Delouya G. A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer. *Target Oncol*. 2017 Oct;12(5):695-701. doi: 10.1007/s11523-017-0516-3.
9. Klil-Drori AJ, Yin H, **Azoulay L**, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Quebec CML Group. Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve

- early molecular response. *Am J Hematol.* 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29. No abstract available.
10. Wissing MD, **Azoulay L**. Postoperative Pelvic Radiotherapy in Patients With Endometrial Cancer May Increase the Risk for Secondary Pelvic Cancers: A Post Hoc Analysis of Results From the TME, PORTEC-1, and PORTEC-2 Trials. *J Clin Oncol.* 2017 Jun 1;35(16):1861-1862. doi: 10.1200/JCO.2017.72.6497. Epub 2017 Mar 13. No abstract available.
  11. Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Greally M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortliczek Z, Prausova J, Batist G, **Azoulay L**, Kavan P. Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study. *Clin Colorectal Cancer.* 2017 Dec;16(4):334-342. doi: 10.1016/j.clcc.2017.03.008. Epub 2017 Mar 21.
  12. **Azoulay L**, Suissa S. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. *Diabetes Care.* 2017 May;40(5):706-714. doi: 10.2337/dc16-1943. Review.
  13. Hicks BM, Yin H, Sinyavskaya L, Suissa S, **Azoulay L**, Brassard P. Metformin and the incidence of viral associated cancers in patients with type 2 diabetes. *Int J Cancer.* 2017 Jul 1;141(1):121-128. doi: 10.1002/ijc.30733. Epub 2017 Apr 24.
  14. Klil-Drori AJ, Yin H, Abenhaim HA, du Fort GG, **Azoulay L**. Prolactin-Elevating Antipsychotics and the Risk of Endometrial Cancer. *J Clin Psychiatry.* 2017 Jun;78(6):714-719. doi: 10.4088/JCP.15m10532.
  15. Greenaway C, **Azoulay L**, Allard R, Cox J, Tran VA, Abou Chakra CN, Steele R, Klein M. A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. *BMC Infect Dis.* 2017 Feb 13;17(1):140. doi: 10.1186/s12879-017-2242-y.
  16. Hicks BM, Yin H, Bladou F, Ernst P, **Azoulay L**. Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia. *Thorax.* 2017 Jul;72(7):596-597. doi: 10.1136/thoraxjnl-2016-209512. Epub 2016 Dec 16.
  17. Khosrow-Khavar F, Rej S, Yin H, Aprikian A, **Azoulay L**. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. *J Clin Oncol.* 2017 Jan 10;35(2):201-207. Epub 2016 Nov 21.
  18. Mandilaras V, Bouganim N, Yin H, Asselah J, **Azoulay L**. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. *Br J Cancer.* 2017 Jan 3;116(1):103-108. doi: 10.1038/bjc.2016.375. Epub 2016 Nov 15.
  19. Klil-Drori AJ, **Azoulay L**, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? *Nat Rev Clin Oncol.* 2017 Feb;14(2):85-99. doi: 10.1038/nrclinonc.2016.120. Epub 2016 Aug 9. Review.
  20. Hicks BM, Yin H, Yu OH, Pollak MN, Platt RW, **Azoulay L**. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. *BMJ.* 2016 Oct 20;355:i5340. doi: 10.1136/bmj.i5340.
  21. Klil-Drori AJ, **Azoulay L**. Reply to Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, and Pär Stattin's Letter to the Editor re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. *Eur Urol* 2016;70:56-61. *Eur Urol.* 2017 Feb;71(2):e63. doi: 10.1016/j.eururo.2016.08.022. Epub 2016 Aug 25.

### Mark Basik

1. Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, **Basik M**, Petrecca K, Asselah J, Meterissian S, Guiot MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. *Cell Rep.* 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
2. Légaré S, Chabot C, **Basik M**. SPEN, a new player in primary cilia formation and cell migration in breast cancer. *Breast Cancer Res.* 2017 Sep 6;19(1):104. doi: 10.1186/s13058-017-0897-3.
3. Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, **Basik M**, Johnson NA, Deyell RJ, Rassekh SR, Morin RD. Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. *Sci Rep.* 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.
4. Popp R, Li H, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Chambers AG, Lan C, Poetz O, **Basik M**, Batist G, Borchers CH. Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. *Anal Chem.* 2017 Oct 3;89(19):10592-10600. doi: 10.1021/acs.analchem.7b02934. Epub 2017 Sep 20.
5. Kuerer HM, Vrancken Peeters MTFD, Rea DW, **Basik M**, De Los Santos J, Heil J. Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials. *Ann Surg Oncol.* 2017 Oct;24(10):2855-2862. doi: 10.1245/s10434-017-5926-z. Epub 2017 Aug 1.
6. Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodouloupoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, **Basik M**. The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience. *Mod Pathol.* 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28.

### Gerald Batist

1. Popp R, Li H, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Chambers AG, Lan C, Poetz O, Basik M, **Batist G**, Borchers CH. Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. *Anal Chem.* 2017 Oct 3;89(19):10592-10600. doi: 10.1021/acs.analchem.7b02934. Epub 2017 Sep 20.
2. Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodouloupoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, **Batist G**, Basik M. The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience. *Mod Pathol.* 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28.
3. Ashour AA, Haik MY, Sadek KW, Yalcin HC, Bitharas J, Aboukassim T, **Batist G**, Yasmeeen A, Al Moustafa AE. Substantial toxic effect of water-pipe smoking on the early stage of embryonic development. *Nicotine Tob Res.* 2017 Jun 12. doi: 10.1093/ntr/ntx135. [Epub ahead of print]

4. Suss S, Bhuiyan N, Demirli K, **Batist G**. Toward Implementing Patient Flow in a Cancer Treatment Center to Reduce Patient Waiting Time and Improve Efficiency. *J Oncol Pract*. 2017 Jun;13(6):e530-e537. doi: 10.1200/JOP.2016.020008. Epub 2017 May 4.
5. Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Grealley M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortliczek Z, Prausova J, **Batist G**, Azoulay L, Kavan P. Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study. *Clin Colorectal Cancer*. 2017 Dec;16(4):334-342. doi: 10.1016/j.clcc.2017.03.008. Epub 2017 Mar 21.
6. Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, **Batist G**, Kavan P, Raoul JL. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. *Medicine (Baltimore)*. 2017 Apr;96(16):e6544. doi: 10.1097/MD.00000000000006544.

### **Nicole Beauchemin**

1. Arabzadeh A, McGregor K, Breton V, Van Der Kraak L, Akavia UD, Greenwood CMT, **Beauchemin N**. EphA2 signaling is impacted by carcinoembryonic antigen cell adhesion molecule 1-L expression in colorectal cancer liver metastasis in a cell context-dependent manner. *Oncotarget*. 2017 Nov 1;8(61):104330-104346. doi: 10.18632/oncotarget.22236. eCollection 2017 Nov 28.
2. Dankner M, Gray-Owen SD, Huang YH, Blumberg RS, **Beauchemin N**. CEACAM1 as a multi-purpose target for cancer immunotherapy. *Oncoimmunology*. 2017 May 16;6(7):e1328336. doi: 10.1080/2162402X.2017.1328336. eCollection 2017. Review.
3. Simoneau E, Chicoine J, Negi S, Salman A, Lazaris A, Hassanain M, **Beauchemin N**, Petrillo S, Valenti D, Amre R, Metrakos P. Next generation sequencing of progressive colorectal liver metastases after portal vein embolization. *Clin Exp Metastasis*. 2017 Jun;34(5):351-361. doi: 10.1007/s10585-017-9855-9. Epub 2017 Jul 31.
4. Lévesque N, Christensen KE, Van Der Kraak L, Best AF, Deng L, Caldwell D, MacFarlane AJ, **Beauchemin N**, Rozen R. Murine MTHFD1-synthetase deficiency, a model for the human MTHFD1 R653Q polymorphism, decreases growth of colorectal tumors. *Mol Carcinog*. 2017 Mar;56(3):1030-1040. doi: 10.1002/mc.22568. Epub 2016 Nov 1.

### **Franck Bladou**

1. Probst S, **Bladou F**, Abikhzer G. Extraosseous Extension of Aggressive Vertebral Hemangioma as a Potential Pitfall on 68Ga-PSMA PET/CT. *Clin Nucl Med*. 2017 Aug;42(8):624-625. doi: 10.1097/RLU.0000000000001731.
2. Gauvin S, Cerantola Y, Haberer E, Pelsser V, Probst S, **Bladou F**, Anidjar M. Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent. *Can Urol Assoc J*. 2017 Jan-Feb;11(1-2):47-52. doi: 10.5489/cuaj.4068.
3. Cerantola Y, Ploussard G, Kassouf W, Anidjar M, **Bladou F**. Does teaching of robotic partial nephrectomy affect renal function and perioperative outcomes? *Urol Oncol*. 2017 May;35(5):227-233. doi: 10.1016/j.urolonc.2016.12.001. Epub 2017 Jan 6.

- Hicks BM, Yin H, **Bladou F**, Ernst P, Azoulay L. Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia. *Thorax*. 2017 Jul;72(7):596-597. doi: 10.1136/thoraxjnl-2016-209512. Epub 2016 Dec 16.

### **Christoph Borchers**

- Mohammed Y, van Vlijmen BJ, Yang J, Percy AJ, Palmblad M, **Borchers CH**, Rosendaal FR. Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer. *Blood Adv*. 2017 Jun 20;1(15):1080-1087. doi: 10.1182/bloodadvances.2017007955. eCollection 2017 Jun 27.
- Eshghi A, **Borchers CH**. Multiple Reaction Monitoring Using Double Isotopologue Peptide Standards for Protein Quantification. *Methods Mol Biol*. 2017 Dec 19. doi: 10.1007/7651\_2017\_112. [Epub ahead of print]
- Urao N, Mirza RE, Corbiere TF, Hollander Z, **Borchers CH**, Koh TJ. Thrombospondin-1 and disease progression in dysferlinopathy. *Hum Mol Genet*. 2017 Dec 15;26(24):4951-4960. doi: 10.1093/hmg/ddx378.
- Han J, Higgins R, Lim MD, Lin K, Yang J, **Borchers CH**. Short-Term Stabilities of 21 Amino Acids in Dried Blood Spots. *Clin Chem*. 2017 Nov 2. pii: clinchem.2017.278457. doi: 10.1373/clinchem.2017.278457. [Epub ahead of print] No abstract available.
- Dilworth D, Upadhyay SK, Bonnafous P, Edoo AB, Bourbigot S, Pesek-Jardim F, Gudavicius G, Serpa JJ, Petrotchenko EV, **Borchers CH**, Nelson CJ, Mackereth CD. The basic tilted helix bundle domain of the prolyl isomerase FKBP25 is a novel double-stranded RNA binding module. *Nucleic Acids Res*. 2017 Nov 16;45(20):11989-12004. doi: 10.1093/nar/gkx852.
- Bowden JA, Heckert A, Ulmer CZ, Jones CM, Koelmel JP, Abdullah L, Ahonen L, Alnouti Y, Armando AM, Asara JM, Bamba T, Barr JR, Bergquist J, **Borchers CH**, Brandsma J, Breitkopf SB, Cajka T, Cazenave-Gassiot A, Checa A, Cinel MA, Colas RA, Cremers S, Dennis EA, Evans JE, Fauland A, Fiehn O, Gardner MS, Garrett TJ, Gotlinger KH, Han J, Huang Y, Neo AH, Hyötyläinen T, Izumi Y, Jiang H, Jiang H, Jiang J, Kachman M, Kiyonami R, Klavins K, Klose C, Köfeler HC, Kolmert J, Koal T, Koster G, Kuklenyik Z, Kurland IJ, Leadley M, Lin K, Maddipati KR, McDougall D, Meikle PJ, Mellett NA, Monnin C, Moseley MA, Nandakumar R, Oresic M, Patterson R, Peake D, Pierce JS, Post M, Postle AD, Pugh R, Qiu Y, Quehenberger O, Ramrup P, Rees J, Rembiesa B, Reynaud D, Roth MR, Sales S, Schuhmann K, Schwartzman ML, Serhan CN, Shevchenko A, Somerville SE, St John-Williams L, Surma MA, Takeda H, Thakare R, Thompson JW, Torta F, Triebel A, Trötz Müller M, Ubhayasekera SJK, Vuckovic D, Weir JM, Welti R, Wenk MR, Wheelock CE, Yao L, Yuan M, Zhao XH, Zhou S. Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. *J Lipid Res*. 2017 Dec;58(12):2275-2288. doi: 10.1194/jlr.M079012. Epub 2017 Oct 6.
- Mohammed Y, Pan J, Zhang S, Han J, **Borchers CH**. ExSTA: External Standard Addition Method for Accurate High-Throughput Quantitation in Targeted Proteomics Experiments. *Proteomics Clin Appl*. 2017 Sep 11. doi: 10.1002/prca.201600180. [Epub ahead of print]
- Li H, Popp R, Frohlich B, Chen MX, **Borchers CH**. Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI). *J Vis Exp*. 2017 Aug 18;(126). doi: 10.3791/55933.
- Popp R, Li H, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Chambers AG, Lan C, Poetz O, Basik M, Batist G, **Borchers CH**. Immuno-Matrix-Assisted Laser Desorption/Ionization



- Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. *Anal Chem.* 2017 Oct 3;89(19):10592-10600. doi: 10.1021/acs.analchem.7b02934. Epub 2017 Sep 20.
10. Guarna MM, Hoover SE, Huxter E, Higo H, Moon KM, Domanski D, Bixby MEF, Melathopoulos AP, Ibrahim A, Peirson M, Desai S, Micholson D, White R, **Borchers CH**, Currie RW, Pernal SF, Foster LJ. Peptide biomarkers used for the selective breeding of a complex polygenic trait in honey bees. *Sci Rep.* 2017 Aug 21;7(1):8381. doi: 10.1038/s41598-017-08464-2.
  11. M Larina I, Percy AJ, Yang J, **Borchers CH**, M Nosovsky A, I Grigoriev A, N Nikolaev E. Protein expression changes caused by spaceflight as measured for 18 Russian cosmonauts. *Sci Rep.* 2017 Aug 15;7(1):8142. doi: 10.1038/s41598-017-08432-w.
  12. Richard VR, Domanski D, Percy AJ, **Borchers CH**. An online 2D-reversed-phase - Reversed-phase chromatographic method for sensitive and robust plasma protein quantitation. *J Proteomics.* 2017 Sep 25;168:28-36. doi: 10.1016/j.jprot.2017.07.018. Epub 2017 Jul 28.
  13. Pedde RD, Li H, **Borchers CH**, Akbari M. Microfluidic-Mass Spectrometry Interfaces for Translational Proteomics. *Trends Biotechnol.* 2017 Oct;35(10):954-970. doi: 10.1016/j.tibtech.2017.06.006. Epub 2017 Jul 26. Review.
  14. Peixoto RJM, Alves ES, Wang M, Ferreira RBR, Granato A, Han J, Gill H, Jacobson K, Lobo LA, Domingues RMCP, **Borchers CH**, Davies JE, Finlay BB, Antunes LCM. Repression of Salmonella host cell invasion by aromatic small molecules from the human fecal metabolome. *Appl Environ Microbiol.* 2017 Jul 28. pii: AEM.01148-17. doi: 10.1128/AEM.01148-17. [Epub ahead of print]
  15. Brodie NI, Popov KI, Petrotchenko EV, Dokholyan NV, **Borchers CH**. Solving protein structures using short-distance cross-linking constraints as a guide for discrete molecular dynamics simulations. *Sci Adv.* 2017 Jul 7;3(7):e1700479. doi: 10.1126/sciadv.1700479. eCollection 2017 Jul.
  16. LeBlanc A, Michaud SA, Percy AJ, Hardie DB, Yang J, Sinclair NJ, Proudfoot JI, Pistawka A, Smith DS, **Borchers CH**. Multiplexed MRM-Based Protein Quantitation Using Two Different Stable Isotope-Labeled Peptide Isotopologues for Calibration. *J Proteome Res.* 2017 Jul 7;16(7):2527-2536. doi: 10.1021/acs.jproteome.7b00094. Epub 2017 Jun 2.
  17. Li H, Han J, Pan J, Liu T, Parker CE, **Borchers CH**. Current trends in quantitative proteomics - an update. *J Mass Spectrom.* 2017 May;52(5):319-341. doi: 10.1002/jms.3932. Review.
  18. Reynolds LA, Redpath SA, Yurist-Doutsch S, Gill N, Brown EM, van der Heijden J, Brosschot TP, Han J, Marshall NC, Woodward SE, Valdez Y, **Borchers CH**, Perona-Wright G, Finlay BB. Enteric Helminths Promote Salmonella Coinfection by Altering the Intestinal Metabolome. *J Infect Dis.* 2017 Apr 15;215(8):1245-1254. doi: 10.1093/infdis/jix141.
  19. Streijger F, Skinnider MA, Rogalski JC, Balshaw R, Shannon CP, Prudova A, Belanger L, Ritchie L, Tsang A, Christie S, Parent S, Mac-Thiong JM, Bailey C, Urquhart J, Ailon T, Paquette S, Boyd M, Street J, Fisher CG, Dvorak MF, **Borchers CH**, Foster LJ, Kwon BK. A Targeted Proteomics Analysis of Cerebrospinal Fluid after Acute Human Spinal Cord Injury. *J Neurotrauma.* 2017 Jun 15;34(12):2054-2068. doi: 10.1089/neu.2016.4879. Epub 2017 Apr 7.
  20. Li H, Popp R, Chen M, MacNamara EM, Juncker D, **Borchers CH**. Bead-Extractor Assisted Ready-to-Use Reagent System (BEARS) for Immunoprecipitation Coupled to MALDI-MS.

- Anal Chem. 2017 Apr 4;89(7):3834-3839. doi: 10.1021/acs.analchem.6b04169. Epub 2017 Mar 16.
21. **Borchers CH**, Thibault P. Corrigendum to "Introduction to the HUPO 2015 Special Issue" [J. Proteomics (2016) 1-2]. J Proteomics. 2017 Jan 30;152:355-356. doi: 10.1016/j.jprot.2016.12.005. No abstract available.
  22. Qiu YL, Gong JY, Feng JY, Wang RX, Han J, Liu T, Lu Y, Li LT, Zhang MH, Sheps JA, Wang NL, Yan YY, Li JQ, Chen L, **Borchers CH**, Sipos B, Knisely AS, Ling V, Xing QH, Wang JS. Defects in myosin VB are associated with a spectrum of previously undiagnosed low  $\gamma$ -glutamyltransferase cholestasis. Hepatology. 2017 May;65(5):1655-1669. doi: 10.1002/hep.29020. Epub 2017 Mar 23.
  23. Wang X, Han J, Hardie DB, Yang J, Pan J, **Borchers CH**. Metabolomic profiling of prostate cancer by matrix assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry imaging using Matrix Coating Assisted by an Electric Field (MCAEF). Biochim Biophys Acta. 2017 Jul;1865(7):755-767. doi: 10.1016/j.bbapap.2016.12.012. Epub 2016 Dec 23.
  24. Bautista-López NL, Ndao M, Camargo FV, Nara T, Annoura T, Hardie DB, **Borchers CH**, Jardim A. Characterization and Diagnostic Application of Trypanosoma cruzi Trypomastigote Excreted-Secreted Antigens Shed in Extracellular Vesicles Released from Infected Mammalian Cells. J Clin Microbiol. 2017 Mar;55(3):744-758. doi: 10.1128/JCM.01649-16. Epub 2016 Dec 14

### Manuel Borod

1. Vigano AAL, Morais JA, Ciutto L, Rosenthal L, di Tomasso J, Khan S, Olders H, **Borod M**, Kilgour RD. Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients. Clin Nutr. 2017 Oct;36(5):1378-1390. doi: 10.1016/j.clnu.2016.09.008. Epub 2016 Sep 20.

### Nathanial Bouganim

1. Khosrow-Khavar F, Yin H, Barkun A, **Bouganim N**, Azoulay L. Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer. Ann Oncol. 2017 Dec 27. doi: 10.1093/annonc/mdx822. [Epub ahead of print]
2. Desforges P, Esfahani K, **Bouganim N**. Programmed Cell Death Ligand 1-Induced Coma From Diffuse Cerebritis. J Oncol Pract. 2017 Oct 10;JOP2017024992. doi: 10.1200/JOP.2017.024992. [Epub ahead of print] No abstract available.
3. Khosrow-Khavar F, Fillion KB, Al-Qurashi S, Torabi N, **Bouganim N**, Suissa S, Azoulay L. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017 Mar 1;28(3):487-496. doi: 10.1093/annonc/mdw673. Review.
4. Mandilaras V, **Bouganim N**, Yin H, Asselah J, Azoulay L. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. Br J Cancer. 2017 Jan 3;116(1):103-108. doi: 10.1038/bjc.2016.375. Epub 2016 Nov 15.

### Pnina Brodt

1. van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, Majeed AW, Eefsen RL, Coebergh van den Braak RRJ, Lazaris A, Fernandez MC, Galjart B, Laerum OD, Rayes R, Grünhagen DJ, Van de Paer M, Sucaet Y, Mudhar HS, Schwimer M,

- Nyström H, Kockx M, Bird NC, Vidal-Vanaclocha F, Metrakos P, Simoneau E, Verhoef C, Dirix LY, Van Laere S, Gao ZH, **Brodt P**, Reynolds AR, Vermeulen PB. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. *Br J Cancer*. 2017 Nov 7;117(10):1427-1441. doi: 10.1038/bjc.2017.334. Epub 2017 Oct 5.
2. Fernandez MC, Rayes R, Ham B, Wang N, Bourdeau F, Milette S, Llleman M, Bird N, Majeed A, Xu J, Kisselova T, **Brodt P**. The type I insulin-like growth factor regulates the liver stromal response to metastatic colon carcinoma cells. *Oncotarget*. 2016 Oct 12;8(32):52281-52293. doi: 10.18632/oncotarget.12595. eCollection 2017 Aug 8.
  3. Milette S, Sicklick JK, Lowy AM, Brodt P. Molecular Pathways: Targeting the Microenvironment of Liver Metastases. *Clin Cancer Res*. 2017 Nov 1;23(21):6390-6399. doi: 10.1158/1078-0432.CCR-15-1636. Epub 2017 Jun 14.

### **Prosanto Chaudhury**

1. Bhat M, Ghali P, Dupont B, Hilzenrat R, Tazari M, Roy A, **Chaudhury P**, Alvarez F, Carrier M, Bilodeau M. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics. *J Hepatol*. 2017 Feb;66(2):374-381. doi: 10.1016/j.jhep.2016.10.008. Epub 2016 Oct 15.

### **Robin Cohen**

1. Chan LS, Macdonald ME, Carnevale FA, **Cohen SR**. 'I'm only dealing with the acute issues': How medical ward 'busyness' constrains care of the dying. *Health (London)*. 2017 May 1:1363459317708822. doi: 10.1177/1363459317708822. [Epub ahead of print]
2. Olivier-D'Avignon M, Dumont S, Valois P, **Cohen SR**. The needs of siblings of children with a life-threatening illness, part 1: Conceptualization and development of a measure. *Palliat Support Care*. 2017 Dec;15(6):644-664. doi: 10.1017/S1478951516001127. Epub 2017 Jan 26.
3. **Cohen SR**, Sawatzky R, Russell LB, Shahidi J, Heyland DK, Gadermann AM. Measuring the quality of life of people at the end of life: The McGill Quality of Life Questionnaire-Revised. *Palliat Med*. 2017 Feb;31(2):120-129. doi: 10.1177/0269216316659603. Epub 2016 Jul 18.
4. Yamaguchi S, **Cohen SR**, Uza M. Family Caregiving in Japan: The Influence of Cultural Constructs in the Care of Adults With Cancer. *J Fam Nurs*. 2016 Aug;22(3):392-418. doi: 10.1177/1074840716655530. Epub 2016 Jun 30.
5. Olivier d'avignon M, Dumont S, Valois P, **Cohen SR**. The needs of siblings of children with a life-threatening illness, part 2: Psychometric validation of the IBesFEMS. *Palliat Support Care*. 2017 Feb;15(1):20-31. doi: 10.1017/S1478951516000316. Epub 2016 May 27.
6. Stevenson M, Achille M, Liben S, Proulx MC, Humbert N, Petti A, Macdonald ME, **Cohen SR**. Understanding How Bereaved Parents Cope With Their Grief to Inform the Services Provided to Them. *Qual Health Res*. 2017 Apr;27(5):649-664. doi: 10.1177/1049732315622189. Epub 2016 Jul 9.

### **Fabio Cury**

1. Hu J, Aprikian AG, **Cury FL**, Vanhuyse M, Zakaria AS, Richard PO, Perreault S, Dragomir A. Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer. *Clin Genitourin Cancer*.

- 2017 Sep 5. pii: S1558-7673(17)30266-5. doi: 10.1016/j.clgc.2017.08.011. [Epub ahead of print]
2. Bachir BG, Souhami L, Mansure JJ, **Cury F**, Vanhuyse M, Brimo F, Aprikian AG, Tanguay S, Sturgeon J, Kassouf W. Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. *Bladder Cancer*. 2017 Apr 27;3(2):105-112. doi: 10.3233/BLC-160090.
  3. Tiberi D, Rodrigues G, Pickles T, Morris J, Crook J, Martin AG, **Cury F**, Catton C, Lukka H, Warner A, Taussky D. External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. *Can Urol Assoc J*. 2017 Mar-Apr;11(3-4):94-100. doi: 10.5489/cuaj.4084.
  4. Rocha J, Aprikian AG, Vanhuyse M, **Cury FL**, Hu J, Prévost N, Dragomir A. Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. *CMAJ Open*. 2017 Mar 28;5(1):E265-E272. doi: 10.9778/cmajo.20160082. eCollection 2017 Jan-Mar.
  5. Faria S, Ruo R, **Cury F**, Duclos M, Souhami L. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. *Pract Radiat Oncol*. 2017 Jul - Aug;7(4):264-269. doi: 10.1016/j.prro.2017.01.003. Epub 2017 Jan 20.

#### **Slobodan Devic**

1. Liang LH, Tomic N, Vuong T, Aldelaijan S, Bekerat H, DeBlois F, Seuntjens J, **Devic S**. Physics aspects of the Papillon technique-Five decades later. *Brachytherapy*. 2017 Nov 1. pii: S1538-4721(17)30474-9. doi: 10.1016/j.brachy.2017.09.016. [Epub ahead of print]
2. Aldelaijan S, Bekerat H, Buzurovic I, Devlin P, DeBlois F, Seuntjens J, **Devic S**. Dose comparison between TG-43-based calculations and radiochromic film measurements of the Freiburg flap applicator used for high-dose-rate brachytherapy treatments of skin lesions. *Brachytherapy*. 2017 Sep - Oct;16(5):1065-1072. doi: 10.1016/j.brachy.2017.06.011. Epub 2017 Jul 20.
3. Aldelaijan S, Wadi-Ramahi S, Nobah A, Moftah B, **Devic S**, Jastaniyah N. Commissioning of applicator-guided stereotactic body radiation therapy boost with high-dose-rate brachytherapy for advanced cervical cancer using radiochromic film dosimetry. *Brachytherapy*. 2017 Jul - Aug;16(4):893-902. doi: 10.1016/j.brachy.2017.03.009. Epub 2017 Apr 28.
4. Nair JR, DeBlois F, Ong T, **Devic S**, Tomic N, Bekerat H, Rosenbloom L, Sultanem K, Forghani R. Dual-Energy CT: Balance Between Iodine Attenuation and Artifact Reduction for the Evaluation of Head and Neck Cancer. *J Comput Assist Tomogr*. 2017 Nov/Dec;41(6):931-936. doi: 10.1097/RCT.0000000000000617.
5. Rabaeh KA, Basfar AA, Almousa AA, **Devic S**, Moftah B. New normoxic N-(Hydroxymethyl)acrylamide based polymer gel for 3D dosimetry in radiation therapy. *Phys Med*. 2017 Jan;33:121-126. doi: 10.1016/j.ejmp.2016.12.019. Epub 2017 Jan 13.

### Marie Duclos

1. Guilbault C, Garant A, Faria S, Owen S, Ofiara L, **Duclos M**, Hirsh V, Kopek N. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer. *Clin Lung Cancer*. 2017 Sep;18(5):565-571. doi: 10.1016/j.clcc.2017.02.003. Epub 2017 Mar 1.
2. Faria S, Ruo R, Cury F, **Duclos M**, Souhami L. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. *Pract Radiat Oncol*. 2017 Jul - Aug;7(4):264-269. doi: 10.1016/j.prro.2017.01.003. Epub 2017 Jan 20.

### Shirin Enger

1. Famulari G, Ulrich T, Armstrong A, **Enger SA**. Practical aspects of <sup>153</sup>Gd as a radioactive source for use in brachytherapy. *Appl Radiat Isot*. 2017 Dec;130:131-139. doi: 10.1016/j.apradiso.2017.09.028. Epub 2017 Sep 21.
2. Famulari G, Pater P, **Enger SA**. Microdosimetry calculations for monoenergetic electrons using Geant4-DNA combined with a weighted track sampling algorithm. *Phys Med Biol*. 2017 Jul 7;62(13):5495-5508. doi: 10.1088/1361-6560/aa71f6. Epub 2017 May 9.

### Marc Fabian

1. Cieplak-Rotowska MK, Tarnowski K, Rubin M, **Fabian MR**, Sonenberg N, Dadlez M, Niedzwiecka A. Structural Dynamics of the GW182 Silencing Domain Including its RNA Recognition motif (RRM) Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry. *J Am Soc Mass Spectrom*. 2017 Oct 27. doi: 10.1007/s13361-017-1830-9. [Epub ahead of print]
2. Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, **Fabian MR**, Richard S, Alaoui-Jamali M, Orthwein A, McCaffrey L, Witcher M. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. *Sci Adv*. 2017 May 24;3(5):e1601898. doi: 10.1126/sciadv.1601898. eCollection 2017 May.
3. Chapat C, Jafarnejad SM, Matta-Camacho E, Hesketh GG, Gelbart IA, Attig J, Gkogkas CG, Alain T, Stern-Ginossar N, **Fabian MR**, Gingras AC, Duchaine TF, Sonenberg N. Cap-binding protein 4EHP effects translation silencing by microRNAs. *Proc Natl Acad Sci U S A*. 2017 May 23;114(21):5425-5430. doi: 10.1073/pnas.1701488114. Epub 2017 May 9.

### Sergio Faria

1. Guilbault C, Garant A, **Faria S**, Owen S, Ofiara L, Duclos M, Hirsh V, Kopek N. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer. *Clin Lung Cancer*. 2017 Sep;18(5):565-571. doi: 10.1016/j.clcc.2017.02.003. Epub 2017 Mar 1.
2. Turgeon GA, Souhami L, Kopek N, Hirsh V, Ofiara L, **Faria SL**. Thoracic irradiation in 3weeks for limited-stage small cell lung cancer: Is twice a day fractionation really needed? *Cancer Radiother*. 2017 Apr;21(2):89-98. doi: 10.1016/j.canrad.2016.09.015. Epub 2017 Mar 18. Review.
3. **Faria S**, Ruo R, Cury F, Duclos M, Souhami L. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. *Pract Radiat Oncol*. 2017 Jul - Aug;7(4):264-269. doi: 10.1016/j.prro.2017.01.003.

Epub 2017 Jan 20.

4. Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, **Faria S**, Gross CP, Yu JB. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. *Radiother Oncol.* 2016 Nov;121(2):294-298. doi: 10.1016/j.radonc.2016.10.013. Epub 2016 Nov 24.
5. Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundapur V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, **Faria S**, Louie AV, Owen T, Wai E, Ramchandrar K, Chan EK, Julian J, Cline K, Whelan TJ. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. *Clin Lung Cancer.* 2017 Mar;18(2):250-254. doi: 10.1016/j.clcc.2016.08.002. Epub 2016 Oct 3.

### **Cristiano Ferrario**

1. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent JJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; **RANGE study investigators**. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. *Lancet.* 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

### **Lorenzo Ferri**

1. **Ferri L**, Bisulli F, Mai R, Licchetta L, Leta C, Nobili L, Mostacci B, Pippucci T, Tinuper P. A stereo EEG study in a patient with sleep-related hypermotor epilepsy due to DEPDC5 mutation. *Seizure.* 2017 Dec;53:51-54. doi: 10.1016/j.seizure.2017.10.022. Epub 2017 Nov 4.
2. Gosselin-Tardif A, Lie J, Nicolau I, Molina JC, Cools-Lartigue J, Feldman L, Spicer J, Mueller C, **Ferri L**. Gastrectomy with Extended Lymphadenectomy: a North American Perspective. *J Gastrointest Surg.* 2017 Nov 9. doi: 10.1007/s11605-017-3633-5. [Epub ahead of print]
3. **Ferri L**, Filardi M, Moresco M, Pizza F, Vandi S, Antelmi E, Toni F, Zucchelli M, Pierangeli G, Plazzi G. Non-24-Hour Sleep-Wake Rhythm Disorder and Melatonin Secretion Impairment in a Patient With Pineal Cyst. *J Clin Sleep Med.* 2017 Nov 15;13(11):1355-1357. doi: 10.5664/jcsm.6816.
4. Naldi I, Bisulli F, Testa C, Rizzo G, **Ferri L**, Gramegna LL, Licchetta L, Lodi R, Tonon C, Tinuper P. Proton MR Spectroscopy in Patients With Sleep-Related Hypermotor Epilepsy (SHE): Evidence of Altered Cingulate Cortex Metabolism. *Sleep.* 2017 Sep 1;40(9). doi: 10.1093/sleep/zsx115.
5. Molina JC, Misariu AM, Nicolau I, Spicer J, Mulder D, **Ferri LE**, Mueller CL. Same day

- discharge for benign laparoscopic hiatal surgery: a feasibility analysis. *Surg Endosc*. 2017 Aug 4. doi: 10.1007/s00464-017-5769-5. [Epub ahead of print]
- Paci P, Madani A, Lee L, Mata J, Mulder DS, Spicer J, **Ferri LE**, Feldman LS. Economic Impact of an Enhanced Recovery Pathway for Lung Resection. *Ann Thorac Surg*. 2017 Sep;104(3):950-957. doi: 10.1016/j.athoracsur.2017.05.085. Epub 2017 Aug 2.
  - Gowing SD, Chow SC, Cools-Lartigue JJ, Chen CB, Najmeh S, Jiang HY, Bourdeau F, Beauchamp A, Mancini U, Angers I, Giannias B, Spicer JD, Rousseau S, Qureshi ST, **Ferri LE**. Gram-positive pneumonia augments non-small cell lung cancer metastasis via host toll-like receptor 2 activation. *Int J Cancer*. 2017 Aug 1;141(3):561-571. doi: 10.1002/ijc.30734. Epub 2017 May 15.
  - Pittau F, **Ferri L**, Fahoum F, Dubeau F, Gotman J. Contributions of EEG-fMRI to Assessing the Epileptogenicity of Focal Cortical Dysplasia. *Front Comput Neurosci*. 2017 Feb 20;11:8. doi: 10.3389/fncom.2017.00008. eCollection 2017.
  - Najmeh S, Cools-Lartigue J, Rayes RF, Gowing S, Vourtzoumis P, Bourdeau F, Giannias B, Berube J, Rousseau S, **Ferri LE**, Spicer JD. Neutrophil extracellular traps sequester circulating tumor cells via  $\beta$ 1-integrin mediated interactions. *Int J Cancer*. 2017 May 15;140(10):2321-2330. doi: 10.1002/ijc.30635. Epub 2017 Mar 2.
  - Mostacci B, Bisulli F, Vignatelli L, Licchetta L, Di Vito L, Rinaldi C, Trippi I, **Ferri L**, Plazzi G, Provini F, Tinuper P. Incidence of sudden unexpected death in epilepsy in sleep-related hypermotor epilepsy, formerly named nocturnal frontal lobe epilepsy. *Sleep Med*. 2017 Jan;29:98. doi: 10.1016/j.sleep.2016.09.005. Epub 2016 Oct 29. No abstract available.

#### **William Foulkes**

- Baert A, Machackova E, Coene I, Cremin C, Turner K, Portigal-Todd C, Asrat MJ, Nuk J, Mindlin A, Sean Y, MacMillan A, Van Maerken T, Trbusek M, McKinnon W, Wood ME, **Foulkes WD**, Santamariña M, de la Hoya M, Foretova L, Poppe B, Vral A, Rosseel T, De Leeneer K, Vega A, Claes KBM. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2, allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11. *Hum Mutat*. 2017 Dec 27. doi: 10.1002/humu.23390. [Epub ahead of print]
- Goudie C, Witkowski L, Vairy S, McCluggage WG, **Foulkes WD**. Paediatric ovarian tumours and their associated cancer susceptibility syndromes. *J Med Genet*. 2018 Jan;55(1):1-10. doi: 10.1136/jmedgenet-2017-104926. Epub 2017 Nov 24.
- Narod S, Booth CM, **Foulkes WD**. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. *N Engl J Med*. 2017 Nov 2;377(18):1792. doi: 10.1056/NEJMc1711644. No abstract available.
- Galiatsatos P, Labos C, Jeanjean M, Miller K, **Foulkes WD**. Low yield of gastroscopy in patients with Lynch syndrome. *Turk J Gastroenterol*. 2017 Nov;28(6):434-438. doi: 10.5152/tjg.2017.17176. Epub 2017 Oct 25.
- McCluggage WG, Irving JA, Chong AS, Clarke BA, Young RH, **Foulkes WD**, Rivera B. Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis. *Am J Surg Pathol*. 2018 Jan;42(1):137-139. doi: 10.1097/PAS.0000000000000981. No abstract available.
- Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, et al. (**William Foulkes** is one of the authors in this multi-author publication). Identification of ten variants associated with risk

- of estrogen-receptor-negative breast cancer. *Nat Genet.* 2017 Dec;49(12):1767-1778. doi: 10.1038/ng.3785. Epub 2017 Oct 23.
7. Wu MK, Vujanic GM, Fahiminiya S, Watanabe N, Thorner PS, O'Sullivan MJ, Fabian MR, **Foulkes WD**. Anaplastic sarcomas of the kidney are characterized by DICER1 mutations. *Mod Pathol.* 2018 Jan;31(1):169-178. doi: 10.1038/modpathol.2017.100. Epub 2017 Sep 1.
  8. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D'Andrea AD, Chanock SJ, **Foulkes WD**, Getz G. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. *Nat Genet.* 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21.
  9. Saskin A, de Kock L, Sabbaghian N, Apellaniz-Ruiz M, Bozkurt C, Bouron-Dal Soglio D, **Foulkes WD**. A case of neuroblastoma in DICER1 syndrome: Chance finding or noncanonical causation? *Pediatr Blood Cancer.* 2018 Jan;65(1). doi: 10.1002/pbc.26715. Epub 2017 Aug 2.
  10. Lebo MS, Zakoor KR, Chun K, Speevak MD, Waye JS, McCready E, Parboosingh JS, Lamont RE, Feilotter H, Bosdet I, Tucker T, Young S, Karsan A, Charames GS, Agatep R, Spriggs EL, Chisholm C, Vasli N, Daoud H, Jarinova O, Tomaszewski R, Hume S, Taylor S, Akbari MR, Lerner-Ellis J; **Canadian Open Genetics Repository Working Group**. Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR). *Genet Med.* 2017 Jul 20. doi: 10.1038/gim.2017.80. [Epub ahead of print]
  11. Achatz MI, Porter CC, Brugières L, Druker H, Frebourg T, **Foulkes WD**, Kratz CP, Kuiper RP, Hansford JR, Hernandez HS, Nathanson KL, Kohlmann WK, Doros L, Onel K, Schneider KW, Scollon SR, Tabori U, Tomlinson GE, Evans DGR, Plon SE. Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. *Clin Cancer Res.* 2017 Jul 1;23(13):e107-e114. doi: 10.1158/1078-0432.CCR-17-0790. Review.
  12. Kamihara J, Bourdeaut F, **Foulkes WD**, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, States LJ, Walsh MF, Diller LR, Brodeur GM. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. *Clin Cancer Res.* 2017 Jul 1;23(13):e98-e106. doi: 10.1158/1078-0432.CCR-17-0652. Review.
  13. de Kock L, Terzic T, McCluggage WG, Stewart CJR, Shaw P, **Foulkes WD**, Clarke BA. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. *Am J Surg Pathol.* 2017 Sep;41(9):1178-1187. doi: 10.1097/PAS.0000000000000895.
  14. Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, Orthwein A, **Foulkes WD**. Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. *Cancer Res.* 2017 Aug 15;77(16):4517-4529. doi: 10.1158/0008-5472.CAN-17-0190. Epub 2017 Jun 23.
  15. Schultz KAP, Rednam SP, Kamihara J, Doros L, Achatz MI, Wasserman JD, Diller LR, Brugières L, Druker H, Schneider KA, McGee RB, **Foulkes WD**. PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and



- Surveillance Recommendations in Childhood. *Clin Cancer Res.* 2017 Jun 15;23(12):e76-e82. doi: 10.1158/1078-0432.CCR-17-0629. Review.
16. **Foulkes WD**, Kamihara J, Evans DGR, Brugières L, Bourdeaut F, Molenaar JJ, Walsh MF, Brodeur GM, Diller L. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. *Clin Cancer Res.* 2017 Jun 15;23(12):e62-e67. doi: 10.1158/1078-0432.CCR-17-0595. Review.
  17. de Kock L, Rivera B, Revil T, Thorner P, Goudie C, Bouron-Dal Soglio D, Choong CS, Priest JR, van Diest PJ, Tanboon J, Wagner A, Ragoussis J, Choong PF, **Foulkes WD**. Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma. *Br J Cancer.* 2017 Jun 6;116(12):1621-1626. doi: 10.1038/bjc.2017.147. Epub 2017 May 18.
  18. Krüger K, Wik E, Knutsvik G, Nalwoga H, et. al. (**William Foulkes** is one of the authors in this multi-author publication). Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet.* 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.
  19. McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, **Foulkes WD**, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? *Gynecol Oncol.* 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.
  20. Larson NB, McDonnell S, Cannon Albright L, Teerlink C, Stanford J, Ostrander EA, Isaacs WB, Xu J, Cooney KA, Lange E, Schleutker J, Carpten JD, Powell I, Bailey-Wilson JE, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Whittemore AS, Hsieh CL, Wiklund F, Catolona WJ, **Foulkes W**, Mandal D, Eeles R, Kote-Jarai Z, Ackerman MJ, Olson TM, Klein CJ, Thibodeau SN, Schaid DJ. gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. *Genet Epidemiol.* 2017 May;41(4):297-308. doi: 10.1002/gepi.22036. Epub 2017 Feb 16. Erratum in: *Genet Epidemiol.* 2017 Nov;41(7):710.
  21. McCluggage WG, Witkowski L, Clarke BA, **Foulkes WD**. Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm. *Histopathology.* 2017 Jun;70(7):1147-1154. doi: 10.1111/his.13177. Epub 2017 Mar 20.
  22. Goudie C, Coltin H, Witkowski L, Mourad S, Malkin D, **Foulkes WD**. The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. *Pediatr Blood Cancer.* 2017 Aug;64(8). doi: 10.1002/pbc.26441. Epub 2017 Jan 18.
  23. Fahiminiya S, de Kock L, **Foulkes WD**. Biologic and Clinical Perspectives on Thyroid Cancer. *N Engl J Med.* 2016 Dec 8;375(23):2306-2307. doi: 10.1056/NEJMc1613118. No abstract available.
  24. Witkowski L, Donini N, Byler-Dann R, Knost JA, Albrecht S, Berchuck A, McCluggage WG, Hasselblatt M, **Foulkes WD**. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases. *Fam Cancer.* 2017 Jul;16(3):395-399. doi: 10.1007/s10689-016-9957-6.
  25. Bonthron DT, **Foulkes WD**. Genetics meets pathology - an increasingly important relationship. *J Pathol.* 2017 Jan;241(2):119-122. doi: 10.1002/path.4849. Review.

**Eduardo Franco**

1. Greenwald ZR, Fregnani JH, Longatto-Filho A, Watanabe A, Mattos JSC, Vazquez FL, **Franco EL**. The performance of mobile screening units in a breast cancer screening program in Brazil. *Cancer Causes Control*. 2017 Dec 18. doi: 10.1007/s10552-017-0995-7. [Epub ahead of print]
2. Farsi NJ, Rousseau MC, Schlecht N, Castonguay G, Allison P, Nguyen-Tan PF, Soulières D, Coutlée F, Hier M, Madathil S, **Franco EL**, Nicolau B. Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol. *Carcinogenesis*. 2017 Dec 7;38(12):1188-1195. doi: 10.1093/carcin/bgx106.
3. Greenwald ZR, El-Zein M, Bouten S, Ensha H, Vazquez FL, **Franco EL**. Mobile Screening Units for the Early Detection of Cancer: A Systematic Review. *Cancer Epidemiol Biomarkers Prev*. 2017 Dec;26(12):1679-1694. doi: 10.1158/1055-9965.EPI-17-0454. Epub 2017 Oct 4. Review.
4. Malagón T, Burchell AN, El-Zein M, Guénoun J, Tellier PP, Coutlée F, **Franco EL**; HITCH Study Group. Estimating HPV DNA Deposition Between Sexual Partners Using HPV Concordance, Y Chromosome DNA Detection, and Self-reported Sexual Behaviors. *J Infect Dis*. 2017 Dec 5;216(10):1210-1218. doi: 10.1093/infdis/jix477.
5. Smith C, Ding L, Gorbach PM, **Franco EL**, Kahn JA. Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women. *J Pediatr Adolesc Gynecol*. 2017 Sep 21. pii: S1083-3188(17)30464-3. doi: 10.1016/j.jpag.2017.09.008. [Epub ahead of print]
6. Malagón T, Burchell A, El-Zein M, Guénoun J, Tellier PP, Coutlée F, **Franco EL**; HITCH study group. Y Chromosome DNA in Women's Vaginal Samples as a Biomarker of Recent Vaginal Sex and Condom Use With Male Partners in the HPV Infection and Transmission Among Couples Through Heterosexual Activity Cohort Study. *Sex Transm Dis*. 2018 Jan;45(1):28-34. doi: 10.1097/OLQ.0000000000000688.
7. Leo PJ, Madeleine MM, Wang S, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Hallmans G, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, **Franco EL**, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Garland S, Tabrizi SN, Wentzensen N, Sitas F, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA. Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study. *PLoS Genet*. 2017 Aug 14;13(8):e1006866. doi: 10.1371/journal.pgen.1006866. eCollection 2017 Aug.
8. Ogilvie G, Nakisige C, Huh WK, Mehrotra R, **Franco EL**, Jeronimo J. Optimizing secondary prevention of cervical cancer: Recent advances and future challenges. *Int J Gynaecol Obstet*. 2017 Jul;138 Suppl 1:15-19. doi: 10.1002/ijgo.12187. Review.
9. Laprise C, Madathil SA, Schlecht NF, Castonguay G, Soulières D, Nguyen-Tan PF, Allison P, Coutlée F, Hier M, Rousseau MC, **Franco EL**, Nicolau B. Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study. *Oral Oncol*. 2017 Jun;69:56-61. doi: 10.1016/j.oraloncology.2017.03.013. Epub 2017 Apr 10.
10. Malagón T, Burchell A, El-Zein M, Tellier PP, Coutlée F, **Franco EL**; HITCH study group. Assortativity and Mixing by Sexual Behaviors and Sociodemographic Characteristics in Young Adult Heterosexual Dating Partnerships. *Sex Transm Dis*. 2017 Jun;44(6):329-337. doi: 10.1097/OLQ.0000000000000612.

11. Smith L, van Niekerk D, Coldman A, Krajden M, **Franco EL**, Ogilvie G. Independent Scientists Provide Guidance for the Future of Cervical Cancer Screening. *J Obstet Gynaecol Can.* 2017 May;39(5):326-327. doi: 10.1016/j.jogc.2017.02.006. No abstract available.
12. **Franco EL**. L'inconvénient du changement de paradigme dans l'édition savante en sciences biomédicales : l'arrivée des éditeurs prédateurs. *J Obstet Gynaecol Can.* 2017 Jul;39(7):516-518. doi: 10.1016/j.jogc.2017.03.122. Epub 2017 Apr 11. French. No abstract available.
13. Sichero L, El-Zein M, Nunes EM, Ferreira S, **Franco EL**, Villa LL; Ludwig-McGill Cohort Study. Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses. *Cancer Epidemiol Biomarkers Prev.* 2017 Aug;26(8):1312-1320. doi: 10.1158/1055-9965.EPI-17-0081. Epub 2017 Apr 4.
14. **Franco EL**. The Downside of the Shifting Paradigm of Scholarly Publishing in the Biomedical Sciences: Predatory Publishing. *J Obstet Gynaecol Can.* 2017 Jul;39(7):513-515. doi: 10.1016/j.jogc.2017.03.104. Epub 2017 Apr 1. No abstract available.
15. Isidean SD, Tota JE, Shinder GA, **Franco EL**. Population health intervention research: A renewed commitment to promoting a science of solutions. *Prev Med.* 2017 Jul;100:1-2. doi: 10.1016/j.ypmed.2017.03.001. Epub 2017 Mar 18. No abstract available.
16. Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, **Franco EL**, Fung-Kee-Fung M, Gotlieb W, Mayrand MH, McLachlin M, Murphy J, Ogilvie G, Ratnam S. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. *Prev Med.* 2017 May;98:5-14. doi: 10.1016/j.ypmed.2016.11.029. Epub 2017 Feb 6.
17. Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, **Franco EL**, Fung-Kee-Fung M, Gotlieb W, Mayrand MH, McLachlin M, Murphy J, Ogilvie G, Ratnam S. Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening. *Prev Med.* 2017 May;98:15-20. doi: 10.1016/j.ypmed.2016.11.030. Epub 2017 Feb 6.
18. Raifu AO, El-Zein M, Sangwa-Lugoma G, Ramanakumar A, Walter SD, **Franco EL**; Congo Screening Study Group. Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) Performed by Nurse and Physician. *PLoS One.* 2017 Jan 20;12(1):e0170631. doi: 10.1371/journal.pone.0170631. eCollection 2017.
19. Isidean SD, Mayrand MH, Ramanakumar AV, Rodrigues I, Ferenczy A, Ratnam S, Coutlée F, **Franco EL**; CCCaST Study Group. Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results. *Cancer Epidemiol Biomarkers Prev.* 2017 Jun;26(6):923-929. doi: 10.1158/1055-9965.EPI-16-0705. Epub 2017 Jan 17.
20. Greenwald ZR, Huang LN, Wissing MD, **Franco EL**, Gotlieb WH. Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer? *Cancer.* 2017 May 1;123(9):1545-1554. doi: 10.1002/cncr.30529. Epub 2016 Dec 27.
21. Tota JE, Jiang M, Ramanakumar AV, Walter SD, Kaufman JS, Coutlée F, Richardson H, Burchell AN, Koushik A, Mayrand MH, Villa LL, **Franco EL**. Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. *PLoS One.* 2016 Dec 22;11(12):e0166329. doi: 10.1371/journal.pone.0166329. eCollection 2016.
22. Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, Gondara L, **Franco EL**, Coldman AJ, Ogilvie GS, Jang D, Chernesky M, Krajden M. Aptima HPV Assay versus

- Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. *J Clin Virol.* 2017 Feb;87:23-29. doi: 10.1016/j.jcv.2016.12.004. Epub 2016 Dec 11.
23. Coldman AJ, Gondara L, Smith LW, van Niekerk D, Ceballos K, Kraijden M, Cook D, Quinlan DJ, Lee M, Stuart GC, Peacock S, Martin RE, Gentile L, **Franco EL**, Ogilvie GS. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. *Br J Cancer.* 2016 Dec 6;115(12):1487-1494. doi: 10.1038/bjc.2016.368. Epub 2016 Nov 17.
  24. Ogilvie GS, Kraijden M, van Niekerk D, Smith LW, Cook D, Ceballos K, Lee M, Gentile L, Gondara L, Elwood-Martin R, Peacock S, Stuart G, **Franco EL**, Coldman AJ. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. *Int J Cancer.* 2017 Jan 15;140(2):440-448. doi: 10.1002/ijc.30454. Epub 2016 Oct 20.

### **Carolyn Freeman**

1. Montgomery L, Fava P, **Freeman CR**, Hijal T, Maietta C, Parker W, Kildea J. Development and implementation of a radiation therapy incident learning system compatible with local workflow and a national taxonomy. *J Appl Clin Med Phys.* 2017 Nov 22. doi: 10.1002/acm2.12218. [Epub ahead of print]

### **Vincent Giguere**

1. Kim SY, Yang CS, Lee HM, Kim JK, Kim YS, Kim YR, Kim JS, Kim TS, Yuk JM, Dufour CR, Lee SH, Kim JM, Choi HS, **Giguère V**, Jo EK. ESRRA (estrogen-related receptor  $\alpha$ ) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense. *Autophagy.* 2017 Aug 25:1-17. doi: 10.1080/15548627.2017.1339001. [Epub ahead of print]
2. Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, Aprikian AG, Lapointe J, Chevalier S, **Giguère V**. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. *Genes Dev.* 2017 Jul 19. doi: 10.1101/gad.299958.117. [Epub ahead of print]
3. Bae S, Lee MJ, Mun SH, Giannopoulou EG, Yong-Gonzalez V, Cross JR, Murata K, **Giguère V**, van der Meulen M, Park-Min KH. MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor  $ERR\alpha$ . *J Clin Invest.* 2017 Jun 30;127(7):2555-2568. doi: 10.1172/JCI89935. Epub 2017 May 22.
4. Audet-Walsh É, Yee T, Tam IS, **Giguère V**. Inverse Regulation of DHT Synthesis Enzymes  $5\alpha$ -Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer. *Endocrinology.* 2017 Apr 1;158(4):1015-1021. doi: 10.1210/en.2016-1926.
5. Audet-Walsh É, Yee T, McGuirk S, Vernier M, Ouellet C, St-Pierre J, **Giguère V**. Androgen-Dependent Repression of  $ERR\gamma$  Reprograms Metabolism in Prostate Cancer. *Cancer Res.* 2017 Jan 15;77(2):378-389. doi: 10.1158/0008-5472.CAN-16-1204. Epub 2016 Nov 7.

### **Lucy Gilbert**

1. **Gilbert L**, Revil T, Meunier C, Jardon K, Zeng X, Martins C, Arseneau J, Fu L, North K, Schiavi A, Ehrensperger E, Artho G, Lee T, Morris D, Ragoussis J. The empress of

- subterfuge: cancer of the fallopian tube presenting with malapropism. *Lancet*. 2017 Sep 2;390(10098):1003-1004. doi: 10.1016/S0140-6736(17)31586-6.
2. Sun Z, **Gilbert L**, Ciampi A, Basso O. Recruitment challenges in clinical research: Survey of potential participants in a diagnostic study of ovarian cancer. *Gynecol Oncol*. 2017 Sep;146(3):470-476. doi: 10.1016/j.ygyno.2017.06.021. Epub 2017 Jun 27.
  3. Ueno Y, Forghani B, Forghani R, Dohan A, Zeng XZ, Chamming's F, Arseneau J, Fu L, **Gilbert L**, Gallix B, Reinhold C. Endometrial Carcinoma: MR Imaging-based Texture Model for Preoperative Risk Stratification-A Preliminary Analysis. *Radiology*. 2017 Sep;284(3):748-757. doi: 10.1148/radiol.2017161950. Epub 2017 May 10.
  4. Koushik A, Grundy A, Abrahamowicz M, Arseneau J, **Gilbert L**, Gotlieb WH, Lacaille J, Mes-Masson AM, Parent MÉ, Provencher DM, Richardson L, Siemiatycki J. Hormonal and reproductive factors and the risk of ovarian cancer. *Cancer Causes Control*. 2017 May;28(5):393-403. doi: 10.1007/s10552-016-0848-9. Epub 2017 Jan 19.

### **Walter Gotlieb**

1. How JA, O'Farrell P, Amajoud Z, Lau S, Salvador S, How E, **Gotlieb WH**. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. *Minerva Ginecol*. 2017 Nov 28. doi: 10.23736/S0026-4784.17.04179-X. [Epub ahead of print]
2. Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, **Gotlieb WH**, Yasmeen A. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. *BMC Cancer*. 2017 Sep 8;17(1):638. doi: 10.1186/s12885-017-3639-0.
3. Hoskins PJ, **Gotlieb WH**. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. *CA Cancer J Clin*. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7. Review.
4. Blank N, Laskov I, Kessous R, Kogan L, Lau S, Sebag IA, **Gotlieb WH**, Rudski L. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin. *Cancer Chemother Pharmacol*. 2017 Oct;80(4):737-743. doi: 10.1007/s00280-017-3412-8. Epub 2017 Aug 11.
5. Kogan L, Laskov I, Amajoud Z, Abitbol J, Yasmeen A, Oceau D, Fatnassi A, Kessous R, Eisenberg N, Lau S, **Gotlieb WH**, Salvador S. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. *Gynecol Oncol*. 2017 Oct;147(1):30-35. doi: 10.1016/j.ygyno.2017.07.134. Epub 2017 Jul 20.
6. How J, Boldeanu I, Lau S, Salvador S, How E, Gotlieb R, Abitbol J, Halder A, Amajoud Z, Probst S, Brin S, **Gotlieb W**. Unexpected locations of sentinel lymph nodes in endometrial cancer. *Gynecol Oncol*. 2017 Oct;147(1):18-23. doi: 10.1016/j.ygyno.2017.07.125. Epub 2017 Jul 14.
7. Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, **Gotlieb WH**, Jeffrey Lowery W, Rossi EC, Tanner EJ, Wolsky RJ. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. *Gynecol Oncol*. 2017 Aug;146(2):405-415. doi: 10.1016/j.ygyno.2017.05.027. Epub 2017 May 28. Review.
8. Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, Franco EL, Fung-Kee-Fung M, **Gotlieb W**, Mayrand MH, McLachlin M, Murphy J, Ogilvie G, Ratnam S. Introduction of molecular HPV testing as the primary technology in cervical cancer

- screening: Acting on evidence to change the current paradigm. *Prev Med.* 2017 May;98:5-14. doi: 10.1016/j.ypmed.2016.11.029. Epub 2017 Feb 6.
9. Leung A, Abitbol J, Ramana-Kumar AV, Fadlallah B, Kessous R, Cohen S, Lau S, Salvador S, **Gotlieb WH**. Outside the operating room: How a robotics program changed resource utilization on the inpatient Ward. *Gynecol Oncol.* 2017 Apr;145(1):102-107. doi: 10.1016/j.ygyno.2017.01.034. Epub 2017 Feb 4.
  10. How J, Gauthier C, Abitbol J, Lau S, Salvador S, Gotlieb R, Pelmus M, Ferenczy A, Probst S, Brin S, Fatnassi A, **Gotlieb W**. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. *Gynecol Oncol.* 2017 Mar;144(3):503-509. doi: 10.1016/j.ygyno.2017.01.013. Epub 2017 Jan 16.
  11. Koushik A, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, **Gotlieb WH**, Lacaille J, Mes-Masson AM, Parent MÉ, Provencher DM, Richardson L, Siemiatycki J. Hormonal and reproductive factors and the risk of ovarian cancer. *Cancer Causes Control.* 2017 May;28(5):393-403. doi: 10.1007/s10552-016-0848-9. Epub 2017 Jan 19.
  12. Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, Lau S, **Gotlieb WH**. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecol Oncol.* 2017 Mar;144(3):474-479. doi: 10.1016/j.ygyno.2016.12.017. Epub 2016 Dec 29.
  13. Greenwald ZR, Huang LN, Wissing MD, Franco EL, **Gotlieb WH**. Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer? *Cancer.* 2017 May 1;123(9):1545-1554. doi: 10.1002/cncr.30529. Epub 2016 Dec 27.
  14. Abitbol J, Cohn R, Hunter S, Rombaldi M, Cohen E, Kessous R, Large N, Reiss A, Lau S, Salvador S, Gotlieb WH. Minimizing pain medication use and its associated costs following robotic surgery. *Gynecol Oncol.* 2017 Jan;144(1):187-192. doi: 10.1016/j.ygyno.2016.11.014. Epub 2016 Nov 11.

### **Celia Greenwood**

1. Arabzadeh A, McGregor K, Breton V, Van Der Kraak L, Akavia UD, **Greenwood CMT**, Beauchemin N. EphA2 signaling is impacted by carcinoembryonic antigen cell adhesion molecule 1-L expression in colorectal cancer liver metastasis in a cell context-dependent manner. *Oncotarget.* 2017 Nov 1;8(61):104330-104346. doi: 10.18632/oncotarget.22236. eCollection 2017 Nov 28.
2. Timpson NJ, **Greenwood CMT**, Soranzo N, Lawson DJ, Richards JB. Genetic architecture: the shape of the genetic contribution to human traits and disease. *Nat Rev Genet.* 2017 Dec 11. doi: 10.1038/nrg.2017.101. [Epub ahead of print] Review.
3. Lakhal-Chaieb L, **Greenwood CMT**, Ouhourane M, Zhao K, Abdous B, Oualkacha K. A smoothed EM-algorithm for DNA methylation profiles from sequencing-based methods in cell lines or for a single cell type. *Stat Appl Genet Mol Biol.* 2017 Nov 27;16(5-6):333-347. doi: 10.1515/sagmb-2016-0062.
4. Xu W, Ma J, **Greenwood CMT**, Paterson AD, Bull SB. Model-Free Linkage Analysis of a Binary Trait. *Methods Mol Biol.* 2017;1666:343-373. doi: 10.1007/978-1-4939-7274-6\_17.
5. Mei S, Karimnezhad A, Forest M, Bickel DR, **Greenwood CMT**. The performance of a new local false discovery rate method on tests of association between coronary artery disease (CAD) and genome-wide genetic variants. *PLoS One.* 2017 Sep 20;12(9):e0185174. doi: 10.1371/journal.pone.0185174. eCollection 2017.

6. Kemp JP, Morris JA, Medina-Gomez C, Forgetta V, et al. (**Celia Greenwood** is one of the authors in this multi-author publication). Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. *Nat Genet.* 2017 Oct;49(10):1468-1475. doi: 10.1038/ng.3949. Epub 2017 Sep 4.
7. Manousaki D, Dudding T, Haworth S, Hsu YH, (**Celia Greenwood** is one of the authors in this multi-author publication). Low-Frequency Synonymous Coding Variation in CYP2R1 Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis. *Am J Hum Genet.* 2017 Aug 3;101(2):227-238. doi: 10.1016/j.ajhg.2017.06.014. Epub 2017 Jul 27.
8. Tachmazidou I, Süveges D, Min JL, Ritchie GRS, (**Celia Greenwood** is one of the authors in this multi-author publication) and arcOGEN Consortium; Understanding Society Scientific Group; UK10K Consortium. Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits. *Am J Hum Genet.* 2017 Jun 1;100(6):865-884. doi: 10.1016/j.ajhg.2017.04.014. Epub 2017 May 25.
9. Wang C, Sun J, Guillaume B, Ge T, Hibar DP, **Greenwood CMT**, Qiu A; Alzheimer's Disease Neuroimaging Initiative. A Set-Based Mixed Effect Model for Gene-Environment Interaction and Its Application to Neuroimaging Phenotypes. *Front Neurosci.* 2017 Apr 6;11:191. doi: 10.3389/fnins.2017.00191. eCollection 2017.
10. Hudson M, Bernatsky S, Colmegna I, Lora M, Pastinen T, Klein Oros K, **Greenwood CMT**. Novel insights into systemic autoimmune rheumatic diseases using shared molecular signatures and an integrative analysis. *Epigenetics.* 2017 Jun 3;12(6):433-440. doi: 10.1080/15592294.2017.1303581. Epub 2017 Apr 7.
11. Forest M, Iturria-Medina Y, Goldman JS, Kleinman CL, Lovato A, Oros Klein K, Evans A, Ciampi A, Labbe A, **Greenwood CMT**. Gene networks show associations with seed region connectivity. *Hum Brain Mapp.* 2017 Jun;38(6):3126-3140. doi: 10.1002/hbm.23579. Epub 2017 Mar 21.
12. McGregor K, Labbe A, **Greenwood CM**. Response to: Correcting for cell-type effects in DNA methylation studies: reference-based method outperforms latent variable approaches in empirical studies. *Genome Biol.* 2017 Jan 30;18(1):25. doi: 10.1186/s13059-017-1149-7.

### **Melissa Henry**

1. **Henry M**, Frenkiel S, Chartier G, MacDonald C, Payne RJ, Black MJ, Mlynarek AM, Zeitouni A, Kost K, Loisel C, Ehrler A, Rosberger Z, Tamilia M, Chang YX, de la Mora C, Arbaud C, Hier MP. Thyroid cancer patients receiving an interdisciplinary team-based care approach (ITCA-ThyCa) appear to display better outcomes: Program evaluation results indicating a need for further integrated care and support. *Psychooncology.* 2017 Nov 25. doi: 10.1002/pon.4590. [Epub ahead of print]

### **Michael Hier**

1. Henry M, Frenkiel S, Chartier G, MacDonald C, Payne RJ, Black MJ, Mlynarek AM, Zeitouni A, Kost K, Loisel C, Ehrler A, Rosberger Z, Tamilia M, Chang YX, de la Mora C, Arbaud C, **Hier MP**. Thyroid cancer patients receiving an interdisciplinary team-based care approach (ITCA-ThyCa) appear to display better outcomes: Program evaluation results indicating a need for further integrated care and support. *Psychooncology.* 2017 Nov 25. doi: 10.1002/pon.4590. [Epub ahead of print]
2. Farsi NJ, Rousseau MC, Schlecht N, Castonguay G, Allison P, Nguyen-Tan PF, Soulières D, Coutlée F, **Hier M**, Madathil S, Franco EL, Nicolau B. Aetiological heterogeneity of head

- and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol. *Carcinogenesis*. 2017 Dec 7;38(12):1188-1195. doi: 10.1093/carcin/bgx106.
3. Lubov J, Maschietto M, Ibrahim I, Mlynarek A, **Hier M**, Kowalski LP, Alaoui-Jamali MA, da Silva SD. Meta-analysis of microRNAs expression in head and neck cancer: uncovering association with outcome and mechanisms. *Oncotarget*. 2017 Jul 13;8(33):55511-55524. doi: 10.18632/oncotarget.19224. eCollection 2017 Aug 15.
  4. Roskies MG, Fang D, Abdallah MN, Charbonneau AM, Cohen N, Jordan JO, **Hier MP**, Mlynarek A, Tamimi F, Tran SD. Three-dimensionally printed polyetherketoneketone scaffolds with mesenchymal stem cells for the reconstruction of critical-sized mandibular defects. *Laryngoscope*. 2017 Nov;127(11):E392-E398. doi: 10.1002/lary.26781. Epub 2017 Aug 4.
  5. Laprise C, Madathil SA, Schlecht NF, Castonguay G, Soulières D, Nguyen-Tan PF, Allison P, Coutlée F, **Hier M**, Rousseau MC, Franco EL, Nicolau B. Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCE Life case-control study. *Oral Oncol*. 2017 Jun;69:56-61. doi: 10.1016/j.oraloncology.2017.03.013. Epub 2017 Apr 10.
  6. Sasson M, Kay-Rivest E, Shoukrun R, Florea A, **Hier M**, Forest VI, Tamilya M, Payne RJ. The T4/T3 quotient as a risk factor for differentiated thyroid cancer: a case control study. *J Otolaryngol Head Neck Surg*. 2017 Apr 4;46(1):28. doi: 10.1186/s40463-017-0208-0.
  7. Kay-Rivest E, Tibbo J, Bouhabel S, Tamilya M, Leboeuf R, Forest VI, **Hier MP**, Savoury L, Payne RJ. The first Canadian experience with the Afirma® gene expression classifier test. *J Otolaryngol Head Neck Surg*. 2017 Apr 4;46(1):25. doi: 10.1186/s40463-017-0201-7.

### **Vera Hirsh**

1. Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, **Hirsh V**, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzaone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. *ESMO Open*. 2017 Aug 17;2(3):e000219. doi: 10.1136/esmoopen-2017-000219. eCollection 2017.
2. Wu YL, **Hirsh V**, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). *Patient*. 2017 Nov 24. doi: 10.1007/s40271-017-0287-z. [Epub ahead of print]
3. Ascierto PA, Daniele B, Hammers H, **Hirsh V**, Kim J, Licitra L, Nanda R, Pignata S. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. *J Transl Med*. 2017 Oct 11;15(1):205. doi: 10.1186/s12967-017-1309-2.
4. Felip E, **Hirsh V**, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. *Clin Lung Cancer*. 2018 Jan;19(1):74-83.e11. doi: 10.1016/j.clcc.2017.06.002. Epub 2017 Jun 23.



5. Morin-Ben Abdallah S, **Hirsh V**. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. *Front Oncol*. 2017 May 16;7:97. doi: 10.3389/fonc.2017.00097. eCollection 2017. Review.
6. **Hirsh V**. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. *Onco Targets Ther*. 2017 May 11;10:2513-2526. doi: 10.2147/OTT.S104177. eCollection 2017. Review.
7. Paz-Ares L, Tan EH, O'Byrne K, Zhang L, **Hirsh V**, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. *Ann Oncol*. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611.
8. Guilbault C, Garant A, Faria S, Owen S, Ofiara L, Duclos M, **Hirsh V**, Kopek N. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer. *Clin Lung Cancer*. 2017 Sep;18(5):565-571. doi: 10.1016/j.clcc.2017.02.003. Epub 2017 Mar 1.
9. Turgeon GA, Souhami L, Kopek N, **Hirsh V**, Ofiara L, Faria SL. Thoracic irradiation in 3weeks for limited-stage small cell lung cancer: Is twice a day fractionation really needed? *Cancer Radiother*. 2017 Apr;21(2):89-98. doi: 10.1016/j.canrad.2016.09.015. Epub 2017 Mar 18. Review.
10. Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, **Hirsh V**, Gibson N, Massey D, Kim M, Yang JC. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. *Br J Cancer*. 2017 Jan 17;116(2):175-185. doi: 10.1038/bjc.2016.420. Epub 2016 Dec 22

#### **Maritza Hobson**

1. Hickling S, Lei H, **Hobson M**, Léger P, Wang X, El Naqa I. Experimental evaluation of x-ray acoustic computed tomography for radiotherapy dosimetry applications. *Med Phys*. 2017 Feb;44(2):608-617. doi: 10.1002/mp.12039. Epub 2017 Jan 25.

#### **Arezu Jahani-Asl**

1. Laaper M, Haque T, Slack RS, **Jahani-Asl A**. Modeling Neuronal Death and Degeneration in Mouse Primary Cerebellar Granule Neurons. *J Vis Exp*. 2017 Nov 6;(129). doi: 10.3791/55871.
2. Mohan S, Bonni A, **Jahani-Asl A**. Targeting OSMR in glioma stem cells. *Oncotarget*. 2017 Mar 7;8(10):16103-16104. doi: 10.18632/oncotarget.15066.

#### **Kris Jardon**

1. Gilbert L, Revil T, Meunier C, **Jardon K**, Zeng X, Martins C, Arseneau J, Fu L, North K, Schiavi A, Ehrensperger E, Artho G, Lee T, Morris D, Ragoussis J. The empress of subterfuge: cancer of the fallopian tube presenting with malapropism. *Lancet*. 2017 Sep 2;390(10098):1003-1004. doi: 10.1016/S0140-6736(17)31586-6.

#### **Nathalie Johnson**

1. Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M,

- Johnson NA**, Deyell RJ, Rassekh SR, Morin RD. Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. *Sci Rep*. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.
- Owen C, Christofides A, **Johnson N**, Lawrence T, MacDonald D, Ward C. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. *Leuk Lymphoma*. 2017 Dec;58(12):2777-2785. doi: 10.1080/10428194.2017.1318439. Epub 2017 May 16.
  - Chen R, Zinzani PL, Fanale MA, Armand P, **Johnson NA**, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. *J Clin Oncol*. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25.
  - Knecht H, **Johnson NA**, Haliotis T, Lichtensztejn D, Mai S. Disruption of direct 3D telomere-TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed-Sternberg cells. *Lab Invest*. 2017 Jul;97(7):772-781. doi: 10.1038/labinvest.2017.33. Epub 2017 Apr 24.

#### **Petr Kavan**

- Ibrahim M, Muanza T, Smirnow N, Sateren W, Fournier B, **Kavan P**, Palumbo M, Dalfen R, Dalzell MA. A Pilot Randomized Controlled Trial on the Effects of a Progressive Exercise Program on the Range of Motion and Upper Extremity Grip Strength in Young Adults With Breast Cancer. *Clin Breast Cancer*. 2017 Jun 24. pii: S1526-8209(17)30032-0. doi: 10.1016/j.clbc.2017.06.007. [Epub ahead of print]
- Ibrahim M, Muanza T, Smirnow N, Sateren W, Fournier B, **Kavan P**, Palumbo M, Dalfen R, Dalzell MA. Time course of upper limb function and return-to-work post-radiotherapy in young adults with breast cancer: a pilot randomized control trial on effects of targeted exercise program. *J Cancer Surviv*. 2017 Dec;11(6):791-799. doi: 10.1007/s11764-017-0617-0. Epub 2017 May 3.
- Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Grealley M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortlicek Z, Prausova J, Batist G, Azoulay L, **Kavan P**. Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study. *Clin Colorectal Cancer*. 2017 Dec;16(4):334-342. doi: 10.1016/j.clcc.2017.03.008. Epub 2017 Mar 21.
- Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, **Kavan P**, Raoul JL. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. *Medicine (Baltimore)*. 2017 Apr;96(16):e6544. doi: 10.1097/MD.0000000000006544.
- Gilabert M, Rho YS, Kavan P. Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas. *Oncology*. 2017;92(3):170-172. doi: 10.1159/000452279. Epub 2016 Nov 12.

#### **Neil Kopek**

- Guilbault C, Garant A, Faria S, Owen S, Ofiara L, Duclos M, Hirsh V, **Kopek N**. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy

With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer. *Clin Lung Cancer*. 2017 Sep;18(5):565-571. doi: 10.1016/j.clcc.2017.02.003. Epub 2017 Mar 1.

2. Laflamme P, Doucet C, Sirois C, **Kopek N**, Vanhuysse M. Stereotactic radiation therapy for residual chemorefractory primary mediastinal non-seminomatous germ cell tumor after surgical thoracotomy. *Pract Radiat Oncol*. 2017 Jul - Aug;7(4):260-263. doi: 10.1016/j.prro.2017.01.004. Epub 2017 Jan 7.

### **Antonis Koromilas**

1. Guan BJ, van Hoef V, Jobava R, Elroy-Stein O, Valasek LS, Cargnello M, Gao XH, Krokowski D, Merrick WC, Kimball SR, Komar AA, **Koromilas AE**, Wynshaw-Boris A, Topisirovic I, Larsson O, Hatzoglou M. A Unique ISR Program Determines Cellular Responses to Chronic Stress. *Mol Cell*. 2017 Dec 7;68(5):885-900.e6. doi: 10.1016/j.molcel.2017.11.007.
2. Ahn R, Sabourin V, Bolt AM, Hébert S, Totten S, De Jay N, Festa MC, Young YK, Im YK, Pawson T, **Koromilas AE**, Muller WJ, Mann KK, Kleinman CL, Ursini-Siegel J. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. *Nat Commun*. 2017 Mar 9;8:14638. doi: 10.1038/ncomms14638.
3. Goldberg AA, Nkengfac B, Sanchez AM, Moroz N, Qureshi ST, **Koromilas AE**, Wang S, Burelle Y, Hussain SN, Kristof AS. Regulation of ULK1 Expression and Autophagy by STAT1. *J Biol Chem*. 2017 Feb 3;292(5):1899-1909. doi: 10.1074/jbc.M116.771584. Epub 2016 Dec 23.
4. Farabaugh KT, Majumder M, Guan BJ, Jobava R, Wu J, Krokowski D, Gao XH, Schuster A, Longworth M, Chan ED, Bianchi M, Dey M, **Koromilas AE**, Ramakrishnan P, Hatzoglou M. Protein Kinase R Mediates the Inflammatory Response Induced by Hyperosmotic Stress. *Mol Cell Biol*. 2017 Feb 1;37(4). pii: e00521-16. doi: 10.1128/MCB.00521-16. Print 2017 Feb 15.

### **Pierre Laneuville**

1. Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, **Laneuville P**, Mollica L, Busque L, Assouline SE; Quebec CML Group. Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response. *Am J Hematol*. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29. No abstract available.
2. **Laneuville P**. Stopping second-generation TKIs in CML. *Blood*. 2017 Feb 16;129(7):805-806. doi: 10.1182/blood-2016-12-757302.

### **Bernard Lapointe**

1. Hagen NA, Cantin L, Constant J, Haller T, Blaise G, Ong-Lam M, du Souich P, Korz W, **Lapointe B**. Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial. *Pain Res Manag*. 2017;2017:7212713. doi: 10.1155/2017/7212713. Epub 2017 May 7.

### **Ives Levesque**

1. Fortier V, **Levesque IR**. Phase processing for quantitative susceptibility mapping of regions with large susceptibility and lack of signal. *Magn Reson Med*. 2017 Nov 11. doi: 10.1002/mrm.26989. [Epub ahead of print]

2. Alonso-Ortiz E, **Levesque IR**, Pike GB. Impact of magnetic susceptibility anisotropy at 3 T and 7 T on T2\*-based myelin water fraction imaging. *Neuroimage*. 2017 Sep 25. pii: S1053-8119(17)30788-7. doi: 10.1016/j.neuroimage.2017.09.040. [Epub ahead of print] Review.
3. Alonso-Ortiz E, **Levesque IR**, Pike GB. Multi-gradient-echo myelin water fraction imaging: Comparison to the multi-echo-spin-echo technique. *Magn Reson Med*. 2017 Jun 27. doi: 10.1002/mrm.26809. [Epub ahead of print]
4. Ahmed Z, **Levesque IR**. Increased robustness in reference region model analysis of DCE MRI using two-step constrained approaches. *Magn Reson Med*. 2017 Oct;78(4):1547-1557. doi: 10.1002/mrm.26530. Epub 2016 Oct 31.
5. Markel D, **Levesque I**, Larkin J, Léger P, El Naqa I. A 4D biomechanical lung phantom for joint segmentation/registration evaluation. *Phys Med Biol*. 2016 Oct 7;61(19):7012-7030. Epub 2016 Sep 20.
6. Alonso-Ortiz E, **Levesque IR**, Paquin R, Pike GB. Field inhomogeneity correction for gradient echo myelin water fraction imaging. *Magn Reson Med*. 2017 Jul;78(1):49-57. doi: 10.1002/mrm.26334. Epub 2016 Jul 15.

#### Sender Liberman

1. Pecorelli N, Fiore JF Jr, Kaneva P, Somasundram A, Charlebois P, **Liberman AS**, Stein BL, Carli F, Feldman LS. An app for patient education and self-audit within an enhanced recovery program for bowel surgery: a pilot study assessing validity and usability. *Surg Endosc*. 2017 Nov 2. doi: 10.1007/s00464-017-5920-3. [Epub ahead of print]
2. Pecorelli N, Hershorn O, Baldini G, Fiore JF Jr, Stein BL, **Liberman AS**, Charlebois P, Carli F, Feldman LS. Impact of adherence to care pathway interventions on recovery following bowel resection within an established enhanced recovery program. *Surg Endosc*. 2017 Apr;31(4):1760-1771. doi: 10.1007/s00464-016-5169-2. Epub 2016 Aug 18.

#### Carmen Loiselle

1. **Loiselle CG**, Ahmed S. Is Connected Health Contributing to a Healthier Population? *J Med Internet Res*. 2017 Nov 10;19(11):e386. doi: 10.2196/jmir.8309.
2. **Loiselle CG**, Santerre-Theil A. Parenting concerns, parental identity and functional status influence medical treatment decisions of patients with advanced cancer. *Evid Based Nurs*. 2017 Oct;20(4):114. doi: 10.1136/eb-2017-102704. Epub 2017 Aug 4. No abstract available.

#### Koren Mann

1. Dahabieh MS, Ha Z, Di Pietro E, Nichol JN, Bolt AM, Goncalves C, Dupéré-Richer D, Pettersson F, **Mann KK**, Braverman NE, Del Rincón SV, Miller WH Jr. Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. *Cell Death Differ*. 2017 Nov;24(11):1912-1924. doi: 10.1038/cdd.2017.115. Epub 2017 Jul 21.
2. Negro Silva LF, Lemaire M, Lemarié CA, Plourde D, Bolt AM, Chiavatti C, Bohle DS, Slavkovich V, Graziano JH, Lehoux S, **Mann KK**. Effects of Inorganic Arsenic, Methylated Arsenicals, and Arsenobetaine on Atherosclerosis in the Mouse Model and the Role of As3mt-Mediated Methylation. *Environ Health Perspect*. 2017 Jul 5;125(7):077001. doi: 10.1289/EHP806.
3. Baker AH, Wu TH, Bolt AM, Gerstenfeld LC, **Mann KK**, Schlezinger JJ. From the Cover: Tributyltin Alters the Bone Marrow Microenvironment and Suppresses B Cell Development. *Toxicol Sci*. 2017 Jul 1;158(1):63-75. doi: 10.1093/toxsci/kfx067.

- Ahn R, Sabourin V, Bolt AM, Hébert S, Totten S, De Jay N, Festa MC, Young YK, Im YK, Pawson T, Koromilas AE, Muller WJ, **Mann KK**, Kleinman CL, Ursini-Siegel J. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. *Nat Commun.* 2017 Mar 9;8:14638. doi: 10.1038/ncomms14638.
- Barhoumi T, Paradis P, **Mann KK**, Schiffrin EL. Isolation of Immune Cells for Adoptive Transfer. *Methods Mol Biol.* 2017;1527:321-344. doi: 10.1007/978-1-4939-6625-7\_25.

### **Richard Margolese**

- Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, **Margolese RG**, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. *Ann Surg Oncol.* 2017 Jul;24(7):1853-1860. doi: 10.1245/s10434-016-5662-9. Epub 2016 Nov 18.

### **Luke McCaffrey**

- Halaoui R, Rejon C, Chatterjee SJ, Szyzborski J, Meterissian S, Muller WJ, Omeroglu A, **McCaffrey L**. Progressive polarity loss and luminal collapse disrupt tissue organization in carcinoma. *Genes Dev.* 2017 Aug 1;31(15):1573-1587. doi: 10.1101/gad.300566.117. Epub 2017 Sep 8.
- Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, Richard S, Alaoui-Jamali M, Orthwein A, **McCaffrey L**, Witcher M. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. *Sci Adv.* 2017 May 24;3(5):e1601898. doi: 10.1126/sciadv.1601898. eCollection 2017 May.

### **Ari Meguerditchian**

- Westley T, Syrowatka A, Henault D, Rho YS, Khazoom F, Chang SL, Tamblyn R, Mayo N, **Meguerditchian AN**. Patterns and predictors of emergency department visits among older patients after breast cancer surgery: A population-based cohort study. *J Geriatr Oncol.* 2017 Nov 28. pii: S1879-4068(17)30228-X. doi: 10.1016/j.jgo.2017.10.003. [Epub ahead of print]
- Tamblyn R, Winslade N, Lee TC, Motulsky A, **Meguerditchian A**, Bustillo M, Elsayed S, Buckeridge DL, Couture I, Qian CJ, Moraga T, Huang A. Improving patient safety and efficiency of medication reconciliation through the development and adoption of a computer-assisted tool with automated electronic integration of population-based community drug data: the RightRx project. *J Am Med Inform Assoc.* 2017 Oct 11. doi: 10.1093/jamia/ocx107. [Epub ahead of print]
- Syrowatka A, Motulsky A, Kurteva S, Hanley JA, Dixon WG, **Meguerditchian AN**, Tamblyn R. Predictors of distress in female breast cancer survivors: a systematic review. *Breast Cancer Res Treat.* 2017 Sep;165(2):229-245. doi: 10.1007/s10549-017-4290-9. Epub 2017 May 28. Review.

### **Sarkis Meterissian**

- Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, **Meterissian S**, Guiot MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J. A Targetable EGFR-Dependent Tumor-

- Initiating Program in Breast Cancer. *Cell Rep.* 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
2. Marta GN, Poortmans P, de Barros AC, Filassi JR, Freitas Junior R, Audisio RA, Mano MS, **Meterissian S**, DeSnyder SM, Buchholz TA, Hijal T. Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy. *Eur J Surg Oncol.* 2017 Nov;43(11):2036-2043. doi: 10.1016/j.ejso.2017.09.014. Epub 2017 Sep 19.
  3. Halaoui R, Rejon C, Chatterjee SJ, Szymborski J, **Meterissian S**, Muller WJ, Omeroglu A, McCaffrey L. Progressive polarity loss and luminal collapse disrupt tissue organization in carcinoma. *Genes Dev.* 2017 Aug 1;31(15):1573-1587. doi: 10.1101/gad.300566.117. Epub 2017 Sep 8.
  4. Sivakumaran L, Ayinde T, Hamadini F, **Meterissian S**, Razek T, Puckrin R, Munoz J, O'Hearn S, Deckelbaum DL. Support infrastructure available to Canadian residents completing post-graduate global health electives: current state and future directions. *Can Med Educ J.* 2016 Dec 5;7(3):e41-e50. eCollection 2016 Dec.
  5. Marcil G, Wong S, Trabulsi N, Allard-Coutu A, Parsyan A, Omeroglu A, Atinel G, Mesurole B, **Meterissian S**. Fibroepithelial breast lesions diagnosed by core needle biopsy demonstrate a moderate rate of upstaging to phyllodes tumors. *Am J Surg.* 2017 Aug;214(2):318-322. doi: 10.1016/j.amjsurg.2016.12.017. Epub 2016 Dec 27.

#### **Catalin Mihalcioiu**

1. Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodouloupoulos R, Salvucci O, **Mihalcioiu C**, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M. The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience. *Mod Pathol.* 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28.
2. Chia SK, Ellard SL, Mates M, Welch S, **Mihalcioiu C**, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. *Breast Cancer Res.* 2017 May 2;19(1):54. doi: 10.1186/s13058-017-0836-3.

#### **Wilson Miller**

1. Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, **Miller WH Jr**. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. *J Immunother Cancer.* 2017 Nov 21;5(1):83. doi: 10.1186/s40425-017-0290-x.
2. Zhan Y, Guo J, Yang W, Goncalves C, Rzymiski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, **Miller WH Jr**, Del Rincón SV. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. *J Clin Invest.* 2017 Nov 1;127(11):4179-4192. doi: 10.1172/JCI91258. Epub 2017 Oct 16.

- Petrella TM, Robert C, Richtig E, **Miller WH Jr**, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. *Eur J Cancer*. 2017 Nov;86:115-124. doi: 10.1016/j.ejca.2017.08.032. Epub 2017 Oct 4.
- Dahabieh MS, Ha Z, Di Pietro E, Nichol JN, Bolt AM, Goncalves C, Dupéré-Richer D, Pettersson F, Mann KK, Braverman NE, Del Rincón SV, **Miller WH Jr**. Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. *Cell Death Differ*. 2017 Nov;24(11):1912-1924. doi: 10.1038/cdd.2017.115. Epub 2017 Jul 21.
- Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, **Miller WH Jr**, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. *J Clin Oncol*. 2017 Jul 3;JCO2016718023. doi: 10.1200/JCO.2016.71.8023. [Epub ahead of print]
- Esfahani K, **Miller WH Jr**. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. *N Engl J Med*. 2017 May 18;376(20):1989-91. doi: 10.1056/NEJMc1703047. No abstract available.
- Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, **Miller WH Jr**, Robson S, Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. *Eur J Cancer*. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.
- Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, **Miller WH Jr**, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. *Breast Cancer Res*. 2017 May 2;19(1):54. doi: 10.1186/s13058-017-0836-3.
- Chang CH, Bijian K, Qiu D, Su J, Saad A, Dahabieh MS, **Miller WH Jr**, Alaoui-Jamali MA. Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells. *Oncotarget*. 2017 May 9;8(19):31199-31214. doi: 10.18632/oncotarget.16105.
- D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, **Miller WH Jr**, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. *J Clin Oncol*. 2017 Jan 10;35(2):226-235. Epub 2016 Nov 7.

### **Elliot Mitmaker**

- Lee SS, Roche PJ, Giannopoulos PN, **Mitmaker EJ**, Tamilia M, Paliouras M, Trifiro MA. Prostate-specific membrane antigen-directed nanoparticle targeting for extreme nearfield

- ablation of prostate cancer cells. *Tumour Biol.* 2017 Mar;39(3):1010428317695943. doi: 10.1177/1010428317695943.
2. Kluijfhout WP, Drake FT, Pasternak JD, Beninato T, **Mitmaker EJ**, Gosnell JE, Shen WT, Suh I, Freise CE, Duh QY. De novo thyroid cancer following solid organ transplantation-A 25-year experience at a high-volume institution with a review of the literature. *J Surg Oncol.* 2017 Feb;115(2):105-108. doi: 10.1002/jso.24495. Epub 2017 Jan 5. Review.
  3. Madani A, Watanabe Y, Bilgic E, Pucher PH, Vassiliou MC, Aggarwal R, Fried GM, **Mitmaker EJ**, Feldman LS. Measuring intra-operative decision-making during laparoscopic cholecystectomy: validity evidence for a novel interactive Web-based assessment tool. *Surg Endosc.* 2017 Mar;31(3):1203-1212. doi: 10.1007/s00464-016-5091-7. Epub 2016 Jul 13.

### **Thierry Muanza**

1. Ibrahim M, **Muanza T**, Smirnow N, Sateren W, Fournier B, Kavan P, Palumbo M, Dalfen R, Dalzell MA. A Pilot Randomized Controlled Trial on the Effects of a Progressive Exercise Program on the Range of Motion and Upper Extremity Grip Strength in Young Adults With Breast Cancer. *Clin Breast Cancer.* 2017 Jun 24. pii: S1526-8209(17)30032-0. doi: 10.1016/j.clbc.2017.06.007. [Epub ahead of print]
2. Maria OM, Eliopoulos N, **Muanza T**. Radiation-Induced Oral Mucositis. *Front Oncol.* 2017 May 22;7:89. doi: 10.3389/fonc.2017.00089. eCollection 2017. Review.
3. Ibrahim M, **Muanza T**, Smirnow N, Sateren W, Fournier B, Kavan P, Palumbo M, Dalfen R, Dalzell MA. Time course of upper limb function and return-to-work post-radiotherapy in young adults with breast cancer: a pilot randomized control trial on effects of targeted exercise program. *J Cancer Surviv.* 2017 Dec;11(6):791-799. doi: 10.1007/s11764-017-0617-0. Epub 2017 May 3.

### **Alain Nepveu**

1. Kaur S, Ramdzan ZM, Guiot MC, Li L, Leduy L, Ramotar D, Sabri S, Abdulkarim B, **Nepveu A**. CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide. *Neuro Oncol.* 2017 Sep 26. doi: 10.1093/neuonc/nox178. [Epub ahead of print]
2. Ramdzan ZM, Ginjala V, Pinder JB, Chung D, Donovan CM, Kaur S, Leduy L, Dellaire G, Ganesan S, **Nepveu A**. The DNA repair function of CUX1 contributes to radioresistance. *Oncotarget.* 2017 Mar 21;8(12):19021-19038. doi: 10.18632/oncotarget.14875.

### **Sylvain Néron**

1. Handel DL, **Néron S**. Cancer Palliation: Layered Hypnotic Approaches Mending Symptoms, Minding Hope, and Meaning. *Am J Clin Hypn.* 2017 Jul;60(1):33-49. doi: 10.1080/00029157.2017.1299678.

### **Alexandre Orthwein**

1. Salsman J, Masson JY, **Orthwein A**, Dellaire G. CRISPR/Cas9 Gene Editing: From Basic Mechanisms To Improved Strategies For Enhanced Genome Engineering In Vivo. *Curr Gene Ther.* 2017 Nov 21. doi: 10.2174/1566523217666171122094629. [Epub ahead of print]
2. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, **Orthwein A**, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen



- LW, D'Andrea AD, Chanock SJ, Foulkes WD, Getz G. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. *Nat Genet.* 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21.
- Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, **Orthwein A**, Foulkes WD. Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. *Cancer Res.* 2017 Aug 15;77(16):4517-4529. doi: 10.1158/0008-5472.CAN-17-0190. Epub 2017 Jun 23.
  - Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, Richard S, Alaoui-Jamali M, **Orthwein A**, McCaffrey L, Witcher M. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. *Sci Adv.* 2017 May 24;3(5):e1601898. doi: 10.1126/sciadv.1601898. eCollection 2017 May.

#### Scott Owen

- Guilbault C, Garant A, Faria S, **Owen S**, Ofiara L, Duclos M, Hirsh V, Kopek N. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer. *Clin Lung Cancer.* 2017 Sep;18(5):565-571. doi: 10.1016/j.clcc.2017.02.003. Epub 2017 Mar 1.
- Shenouda G, Souhami L, Petrecca K, **Owen S**, Panet-Raymond V, Guiot MC, Corredor AG, Abdulkarim B. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. *Int J Radiat Oncol Biol Phys.* 2017 Mar 1;97(3):487-494. doi: 10.1016/j.ijrobp.2016.11.006. Epub 2016 Nov 15.

#### Lawrence Panasci

- Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, **Panasci L**, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. *Breast Cancer Res Treat.* 2017 Oct 13. doi: 10.1007/s10549-017-4538-4. [Epub ahead of print]
- Bousmail D, Amrein L, Fakhoury JJ, Fakhoury HH, Hsu JCC, **Panasci L**, Sleiman HF. Precision spherical nucleic acids for delivery of anticancer drugs. *Chem Sci.* 2017 Sep 1;8(9):6218-6229. doi: 10.1039/c7sc01619k. Epub 2017 Jul 5.

#### Valerie Panet-Raymond

- Chatterjee A, Serban M, Abdulkarim B, **Panet-Raymond V**, Souhami L, Shenouda G, Sabri S, Jean-Claude B, Seuntjens J. Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site. *Int J Radiat Oncol Biol Phys.* 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.
- Shenouda G, Souhami L, Petrecca K, Owen S, **Panet-Raymond V**, Guiot MC, Corredor AG, Abdulkarim B. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant

Temozolomide for Patients With Glioblastoma. *Int J Radiat Oncol Biol Phys.* 2017 Mar 1;97(3):487-494. doi: 10.1016/j.ijrobp.2016.11.006. Epub 2016 Nov 15.

### **Morag Park**

1. Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, Meterissian S, Guiot MC, Omeroglu A, Kleinman CL, **Park M**, Ragoussis J. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. *Cell Rep.* 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
2. Grandal MM, Havrylov S, Poulsen TT, Koefoed K, Dahlman A, Galler GR, Conrotto P, Collins S, Eriksen KW, Kaufman D, Woude GFV, Jacobsen HJ, Horak ID, Kragh M, Lantto J, Bouquin T, **Park M**, Pedersen MW. Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms. *Mol Cancer Ther.* 2017 Dec;16(12):2780-2791. doi: 10.1158/1535-7163.MCT-17-0374. Epub 2017 Aug 11.
3. Saleh SMI, Bertos N, Gruosso T, Gigoux M, Souleimanova M, Zhao H, Omeroglu A, Hallett MT, **Park M**. Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer. *Cancer Res.* 2017 Sep 1;77(17):4673-4683. doi: 10.1158/0008-5472.CAN-16-3427. Epub 2017 Jun 26.
4. Liu H, Dowdle JA, Khurshid S, Sullivan NJ, Bertos N, Rambani K, Mair M, Daniel P, Wheeler E, Tang X, Toth K, Lause M, Harrigan ME, Eiring K, Sullivan C, Sullivan MJ, Chang SW, Srivastava S, Conway JS, Kladney R, McElroy J, Bae S, Lu Y, Tofigh A, Saleh SMI, Fernandez SA, Parvin JD, Coppola V, Macrae ER, Majumder S, Shapiro CL, Yee LD, Ramaswamy B, Hallett M, Ostrowski MC, **Park M**, Chamberlin HM, Leone G. Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation. *Dev Cell.* 2017 May 22;41(4):392-407.e6. doi: 10.1016/j.devcel.2017.04.024.
5. Shafer MER, Nguyen AHT, Tremblay M, Viala S, Béland M, Bertos NR, **Park M**, Bouchard M. Lineage Specification from Prostate Progenitor Cells Requires Gata3-Dependent Mitotic Spindle Orientation. *Stem Cell Reports.* 2017 Apr 11;8(4):1018-1031. doi: 10.1016/j.stemcr.2017.02.004. Epub 2017 Mar 9.

### **Jerry Pelletier**

1. Robert F, Huang S, **Pelletier J**. CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery. *Curr Gene Ther.* 2017 Nov 21. doi: 10.2174/1566523217666171121164615. [Epub ahead of print]
2. Chu J, Cajal SRY, Sonenberg N, **Pelletier J**. Eukaryotic initiation factor 4F-sidestepping resistance mechanisms arising from expression heterogeneity. *Curr Opin Genet Dev.* 2017 Nov 20;48:89-96. doi: 10.1016/j.gde.2017.11.002. [Epub ahead of print] Review.
3. Choi HY, Ruel I, Malina A, Garrod DR, Oda MN, **Pelletier J**, Schwertani A, Genest J. Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis. *Eur Heart J.* 2017 Jun 29. doi: 10.1093/eurheartj/ehx340. [Epub ahead of print]
4. Könst ZA, Szklarski AR, Pellegrino S, Michalak SE, Meyer M, Zanette C, Cencic R, Nam S, Voora VK, Horne DA, **Pelletier J**, Mobley DL, Yusupova G, Yusupov M, Vanderwal CD. Synthesis facilitates an understanding of the structural basis for translation inhibition by the

- lissoclimides. *Nat Chem.* 2017 Nov;9(11):1140-1149. doi: 10.1038/nchem.2800. Epub 2017 Jul 3.
5. Fok KL, Bose R, Sheng K, Chang CW, Katz-Egorov M, Culty M, Su S, Yang M, Ruan YC, Chan HC, Iavarone A, Lasorella A, Cencic R, **Pelletier J**, Nagano M, Xu W, Wing SS. Huwe1 Regulates the Establishment and Maintenance of Spermatogonia by Suppressing DNA Damage Response. *Endocrinology.* 2017 Nov 1;158(11):4000-4016. doi: 10.1210/en.2017-00396.
  6. Penafuerte C, Feldhammer M, Mills JR, Vinette V, Pike KA, Hall A, Migon E, Karsenty G, **Pelletier J**, Zogopoulos G, Tremblay ML. Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFN $\gamma$  signaling. *Oncoimmunology.* 2017 Apr 28;6(6):e1321185. doi: 10.1080/2162402X.2017.1321185. eCollection 2017.
  7. Deyou T, Marco M, Heydenreich M, Pan F, Gruhonjic A, Fitzpatrick PA, Koch A, Derese S, **Pelletier J**, Rissanen K, Yenesew A, Erdélyi M. Isoflavones and Rotenoids from the Leaves of *Millettia oblata* ssp. *teitensis*. *J Nat Prod.* 2017 Jul 28;80(7):2060-2066. doi: 10.1021/acs.jnatprod.7b00255. Epub 2017 Jun 30.
  8. Carvalho A, Chu J, Meinguet C, Kiss R, Vandenbussche G, Masereel B, Wouters J, Kornienko A, **Pelletier J**, Mathieu V. Data in support of a harmine-derived beta-carboline in vitro effects in cancer cells through protein synthesis. *Data Brief.* 2017 May 5;12:546-551. doi: 10.1016/j.dib.2017.05.006. eCollection 2017 Jun.
  9. Lee T, **Pelletier J**. Dependence of p53-deficient cells on the DHX9 DExH-box helicase. *Oncotarget.* 2017 May 9;8(19):30908-30921. doi: 10.18632/oncotarget.15889.
  10. Davison JR, Lohith KM, Wang X, Bobyk K, Mandadapu SR, Lee SL, Cencic R, Nelson J, Simpkins S, Frank KM, **Pelletier J**, Myers CL, Piotrowski J, Smith HE, Bewley CA. A New Natural Product Analog of Blasticidin S Reveals Cellular Uptake Facilitated by the NorA Multidrug Transporter. *Antimicrob Agents Chemother.* 2017 May 24;61(6). pii: e02635-16. doi: 10.1128/AAC.02635-16. Print 2017 Jun.
  11. Carvalho A, Chu J, Meinguet C, Kiss R, Vandenbussche G, Masereel B, Wouters J, Kornienko A, **Pelletier J**, Mathieu V. A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis. *Eur J Pharmacol.* 2017 Jun 15;805:25-35. doi: 10.1016/j.ejphar.2017.03.034. Epub 2017 Mar 18.
  12. Abbas YM, Laudenbach BT, Martínez-Montero S, Cencic R, Habjan M, Pichlmair A, Damha MJ, **Pelletier J**, Nagar B. Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2'-O methylations. *Proc Natl Acad Sci U S A.* 2017 Mar 14;114(11):E2106-E2115. doi: 10.1073/pnas.1612444114. Epub 2017 Mar 1.
  13. Steinberger J, Chu J, Maïga RI, Sleiman K, **Pelletier J**. Developing anti-neoplastic biotherapeutics against eIF4F. *Cell Mol Life Sci.* 2017 May;74(9):1681-1692. doi: 10.1007/s00018-016-2430-8. Epub 2016 Dec 21. Review.
  14. Nyandoro SS, Munissi JJ, Gruhonjic A, Duffy S, Pan F, Puttreddy R, Holleran JP, Fitzpatrick PA, **Pelletier J**, Avery VM, Rissanen K, Erdélyi M. Polyoxygenated Cyclohexenes and Other Constituents of *Cleistochlamys kirkii* Leaves. *J Nat Prod.* 2017 Jan 27;80(1):114-125. doi: 10.1021/acs.jnatprod.6b00759. Epub 2016 Dec 21.

### Michael Pollak

1. Abrahami D, Yin H, Yu OHY, **Pollak MN**, Azoulay L. Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes. *Epidemiology*. 2017 Dec 26. doi: 10.1097/EDE.0000000000000793. [Epub ahead of print]
2. Alemán JO, Iyengar NM, Walker JM, Milne GL, Da Rosa JC, Liang Y, Giri DD, Zhou XK, **Pollak MN**, Hudis CA, Breslow JL, Holt PR, Dannenberg AJ. Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women. *J Endocr Soc*. 2017 Apr 25;1(6):625-637. doi: 10.1210/js.2017-00020. eCollection 2017 Jun 1.
3. Farland LV, Mu F, Eliassen AH, Hankinson SE, Tworoger SS, Barbieri RL, Dowsett M, **Pollak MN**, Missmer SA. Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. *Cancer Causes Control*. 2017 Dec;28(12):1441-1452. doi: 10.1007/s10552-017-0971-2. Epub 2017 Oct 31.
4. Sanders JL, Guo W, O'Meara ES, Kaplan RC, **Pollak MN**, Bartz TM, Newman AB, Fried LP, Cappola AR. Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study. *J Gerontol A Biol Sci Med Sci*. 2017 Jul 23. doi: 10.1093/gerona/glx143. [Epub ahead of print]
5. Santo L, Teras LR, Giles GG, Weinstein SJ, Albanes D, Wang Y, Pfeiffer RM, Lan Q, Rothman N, Birmann BM, Colditz GA, **Pollak MN**, Purdue MP, Hofmann JN. Circulating resistin levels and risk of multiple myeloma in three prospective cohorts. *Br J Cancer*. 2017 Oct 10;117(8):1241-1245. doi: 10.1038/bjc.2017.282. Epub 2017 Aug 22.
6. Hofmann JN, Mailankody S, Korde N, Wang Y, Tajeja N, Costello R, Zingone A, Hultcrantz M, **Pollak MN**, Purdue MP, Landgren O. Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. *Obesity (Silver Spring)*. 2017 Aug;25(8):1317-1320. doi: 10.1002/oby.21894. Epub 2017 Jun 11.
7. Liao LM, Hofmann JN, Cho E, **Pollak MN**, Chow WH, Purdue MP. Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial. *Cancer Causes Control*. 2017 Jul;28(7):801-807. doi: 10.1007/s10552-017-0901-3. Epub 2017 May 8.
8. **Pollak MN**. Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis. *Nat Rev Clin Oncol*. 2017 May;14(5):268. doi: 10.1038/nrclinonc.2017.57. Epub 2017 Apr 19.
9. Yerushalmi R, Dong B, Chapman JW, Goss PE, **Pollak MN**, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. *Ann Oncol*. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152.
10. Klil-Drori AJ, Azoulay L, **Pollak MN**. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? *Nat Rev Clin Oncol*. 2017 Feb;14(2):85-99. doi: 10.1038/nrclinonc.2016.120. Epub 2016 Aug 9. Review.

### Stéphane Richard

1. Li N, Hébert S, Song J, Kleinman CL, **Richard S**. Transcriptome profiling in preadipocytes identifies long noncoding RNAs as Sam68 targets. *Oncotarget*. 2017 May 11;8(47):81994-82005. doi: 10.18632/oncotarget.17813. eCollection 2017 Oct 10.
2. Thandapani P, Couturier AM, Yu Z, Li X, Couture JF, Li S, Masson JY, **Richard S**. Lysine methylation of FEN1 by SET7 is essential for its cellular response to replicative stress.

- Oncotarget. 2017 May 22;8(39):64918-64931. doi: 10.18632/oncotarget.18070. eCollection 2017 Sep 12.
3. Infantino S, Light A, O'Donnell K, Bryant V, Avery DT, Elliott M, Tangye SG, Belz G, Mackay F, **Richard S**, Tarlinton D. Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation. *Nat Commun*. 2017 Oct 12;8(1):891. doi: 10.1038/s41467-017-01009-1.
  4. Yu Z, Chen T, Hébert J, Li E, **Richard S**. Correction for Yu et al., "A Mouse PRMT1 Null Allele Defines an Essential Role for Arginine Methylation in Genome Maintenance and Cell Proliferation". *Mol Cell Biol*. 2017 Aug 11;37(17). pii: e00298-17. doi: 10.1128/MCB.00298-17. Print 2017 Sep 1. No abstract available.
  5. Darbelli L, Choquet K, **Richard S**, Kleinman CL. Transcriptome profiling of mouse brains with qKI-deficient oligodendrocytes reveals major alternative splicing defects including self-splicing. *Sci Rep*. 2017 Aug 8;7(1):7554. doi: 10.1038/s41598-017-06211-1.
  6. Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, **Richard S**, Alaoui-Jamali M, Orthwein A, McCaffrey L, Witcher M. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. *Sci Adv*. 2017 May 24;3(5):e1601898. doi: 10.1126/sciadv.1601898. eCollection 2017 May.
  7. Blanc RS, **Richard S**. Regenerating muscle with arginine methylation. *Transcription*. 2017 May 27;8(3):175-178. doi: 10.1080/21541264.2017.1291083. Epub 2017 Feb 17.
  8. Song J, Perreault JP, Topisirovic I, **Richard S**. RNA G-quadruplexes and their potential regulatory roles in translation. *Translation (Austin)*. 2016 Oct 4;4(2):e1244031. doi: 10.1080/21690731.2016.1244031. eCollection 2016. Review.
  9. Blanc RS, **Richard S**. Arginine Methylation: The Coming of Age. *Mol Cell*. 2017 Jan 5;65(1):8-24. doi: 10.1016/j.molcel.2016.11.003. Review.
  10. Blanc RS, Vogel G, Li X, Yu Z, Li S, **Richard S**. Arginine Methylation by PRMT1 Regulates Muscle Stem Cell Fate. *Mol Cell Biol*. 2017 Jan 19;37(3). pii: e00457-16. doi: 10.1128/MCB.00457-16. Print 2017 Feb 1.

### **Zeev Rosberger**

1. Shapiro GK, Tatar O, Dube E, Amsel R, Knauper B, Naz A, Perez S, **Rosberger Z**. The vaccine hesitancy scale: Psychometric properties and validation. *Vaccine*. 2017 Dec 27. pii: S0264-410X(17)31796-6. doi: 10.1016/j.vaccine.2017.12.043. [Epub ahead of print]
2. Shapiro GK, Tatar O, Sutton A, Fisher W, Naz A, Perez S, **Rosberger Z**. Correlates of Tinder Use and Risky Sexual Behaviors in Young Adults. *Cyberpsychol Behav Soc Netw*. 2017 Dec;20(12):727-734. doi: 10.1089/cyber.2017.0279. Epub 2017 Dec 6.
3. Perez S, Restle H, Naz A, Tatar O, Shapiro GK, **Rosberger Z**. Parents' involvement in the human papillomavirus vaccination decision for their sons. *Sex Reprod Healthc*. 2017 Dec;14:33-39. doi: 10.1016/j.srhc.2017.08.005. Epub 2017 Aug 24.
4. Tatar O, Perez S, Naz A, Shapiro GK, **Rosberger Z**. Psychosocial correlates of HPV vaccine acceptability in college males: A cross-sectional exploratory study. *Papillomavirus Res*. 2017 Dec;4:99-107. doi: 10.1016/j.pvr.2017.11.001. Epub 2017 Nov 8.
5. Henry M, Frenkiel S, Chartier G, MacDonald C, Payne RJ, Black MJ, Mlynarek AM, Zeitouni A, Kost K, Loisel C, Ehrler A, **Rosberger Z**, Tamilia M, Chang YX, de la Mora C, Arbaud C, Hier MP. Thyroid cancer patients receiving an interdisciplinary team-based care approach (ITCA-ThyCa) appear to display better outcomes: Program evaluation results

- indicating a need for further integrated care and support. *Psychooncology*. 2017 Nov 25. doi: 10.1002/pon.4590. [Epub ahead of print]
6. Shapiro GK, Perez S, Naz A, Tatar O, Guichon JR, Amsel R, Zimet GD, **Rosberger Z**. Investigating Canadian parents' HPV vaccine knowledge, attitudes and behaviour: a study protocol for a longitudinal national online survey. *BMJ Open*. 2017 Oct 11;7(10):e017814. doi: 10.1136/bmjopen-2017-017814.
  7. Perez S, Tatar O, Gilca V, Shapiro GK, Ogilvie G, Guichon J, Naz A, **Rosberger Z**. Untangling the psychosocial predictors of HPV vaccination decision-making among parents of boys. *Vaccine*. 2017 Aug 24;35(36):4713-4721. doi: 10.1016/j.vaccine.2017.07.043. Epub 2017 Jul 27.
  8. Daley EM, Vamos CA, Thompson EL, Zimet GD, **Rosberger Z**, Merrell L, Kline NS. The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. *Papillomavirus Res*. 2017 Jun;3:142-148. doi: 10.1016/j.pvr.2017.04.004. Epub 2017 Apr 23.
  9. Shapiro GK, Guichon J, Prue G, Perez S, **Rosberger Z**. A Multiple Streams analysis of the decisions to fund gender-neutral HPV vaccination in Canada. *Prev Med*. 2017 Jul;100:123-131. doi: 10.1016/j.ypmed.2017.04.016. Epub 2017 Apr 20. Review.
  10. Shapiro GK, Perez S, **Rosberger Z**. The authors respond to "Supporting the call for a gender-neutral human papillomavirus vaccination in Canada". *CMAJ*. 2017 Jan 23;189(3):E119. doi: 10.1503/cmaj.732630. No abstract available.

### Jan Seuntjens

1. Perez JR, Ybarra N, Chagnon F, Serban M, Pare G, Lesur O, **Seuntjens J**, Naqa IE. Image-Guided Fluorescence Endomicroscopy: From Macro- to Micro-Imaging of Radiation-Induced Pulmonary Fibrosis. *Sci Rep*. 2017 Dec 19;7(1):17829. doi: 10.1038/s41598-017-18070-x.
2. Fang D, Su X, Liu Y, Lee JC, **Seuntjens J**, Tran SD. Cell extracts from spleen and adipose tissues restore function to irradiation-injured salivary glands. *J Tissue Eng Regen Med*. 2017 Sep 5. doi: 10.1002/term.2567. [Epub ahead of print] No abstract available.
3. Aldelaijan S, Tomic N, Papaconstadopoulos P, Schneider J, **Seuntjens J**, Shih S, Lewis D, Devic S. Technical Note: Response time evolution of XR-QA2 GafChromic™ film models. *Med Phys*. 2018 Jan;45(1):488-492. doi: 10.1002/mp.12689. Epub 2017 Dec 12.
4. Renaud J, Sarfehnia A, Bancheri J, **Seuntjens J**. Aerrow: A probe-format graphite calorimeter for absolute dosimetry of high-energy photon beams in the clinical environment. *Med Phys*. 2018 Jan;45(1):414-428. doi: 10.1002/mp.12669. Epub 2017 Dec 5.
5. Liang LH, Tomic N, Vuong T, Aldelaijan S, Bekerat H, DeBlois F, **Seuntjens J**, Devic S. Physics aspects of the Papillon technique-Five decades later. *Brachytherapy*. 2017 Nov 1. pii: S1538-4721(17)30474-9. doi: 10.1016/j.brachy.2017.09.016. [Epub ahead of print]
6. Toltz A, Hoesl M, Schuemann J, **Seuntjens J**, Lu HM, Paganetti H. Time-resolved diode dosimetry calibration through Monte Carlo modeling for in vivo passive scattered proton therapy range verification. *J Appl Clin Med Phys*. 2017 Nov;18(6):200-205. doi: 10.1002/acm2.12210. Epub 2017 Oct 29.
7. Watson PGF, Popovic M, **Seuntjens J**. Determination of absorbed dose to water from a miniature kilovoltage x-ray source using a parallel-plate ionization chamber. *Phys Med Biol*. 2017 Dec 19;63(1):015016. doi: 10.1088/1361-6560/aa9560.

8. McEwen M, DeWerd L, Ibbott G, Followill D, Rogers DWO, Seltzer S, **Seuntjens J**, Kawachi T, Katayose T, Kodama T, Miyasaka R. Addendum to the AAPM's TG-51 Protocol for Clinical Reference Dosimetry of High-Energy Photon Beams. *Igaku Butsuri*. 2017;37(1):2-24. doi: 10.11323/jjamp.37.1\_2. Japanese. No abstract available.
9. Chatterjee A, Serban M, Abdulkarim B, Panet-Raymond V, Souhami L, Shenouda G, Sabri S, Jean-Claude B, **Seuntjens J**. Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site. *Int J Radiat Oncol Biol Phys*. 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.
10. Vallières M, Kay-Rivest E, Perrin LJ, Liem X, Furstoss C, Aerts HJWL, Khaouam N, Nguyen-Tan PF, Wang CS, Sultanem K, **Seuntjens J**, El Naqa I. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. *Sci Rep*. 2017 Aug 31;7(1):10117. doi: 10.1038/s41598-017-10371-5.
11. Perez JR, Lee S, Ybarra N, Maria O, Serban M, Jeyaseelan K, Wang LM, **Seuntjens J**, Naqa IE. A comparative analysis of longitudinal computed tomography and histopathology for evaluating the potential of mesenchymal stem cells in mitigating radiation-induced pulmonary fibrosis. *Sci Rep*. 2017 Aug 22;7(1):9056. doi: 10.1038/s41598-017-09021-7.
12. Aldelaijan S, Bekerat H, Buzurovic I, Devlin P, DeBlois F, **Seuntjens J**, Devic S. Dose comparison between TG-43-based calculations and radiochromic film measurements of the Freiburg flap applicator used for high-dose-rate brachytherapy treatments of skin lesions. *Brachytherapy*. 2017 Sep - Oct;16(5):1065-1072. doi: 10.1016/j.brachy.2017.06.011. Epub 2017 Jul 20.
13. Fang D, Shang S, Liu Y, Bakkar M, Sumita Y, **Seuntjens J**, Tran SD. Optimal timing and frequency of bone marrow soup therapy for functional restoration of salivary glands injured by single-dose or fractionated irradiation. *J Tissue Eng Regen Med*. 2017 Jul 17. doi: 10.1002/term.2513. [Epub ahead of print]
14. Renaud MA, Serban M, **Seuntjens J**. On mixed electron-photon radiation therapy optimization using the column generation approach. *Med Phys*. 2017 Aug;44(8):4287-4298. doi: 10.1002/mp.12338. Epub 2017 Jun 30.
15. Aldosary G, Safigholi H, Song W, **Seuntjens J**, Sarfehnia A. Polarity and ion recombination corrections in continuous and pulsed beams for ionization chambers with high Z chamber walls. *Phys Med*. 2017 Mar;35:102-109. doi: 10.1016/j.ejmp.2017.01.019. Epub 2017 Feb 12.
16. Perez JR, Ybarra N, Chagnon F, Serban M, Lee S, **Seuntjens J**, Lesur O, El Naqa I. Tracking of Mesenchymal Stem Cells with Fluorescence Endomicroscopy Imaging in Radiotherapy-Induced Lung Injury. *Sci Rep*. 2017 Jan 19;7:40748. doi: 10.1038/srep40748.
17. Papaconstadopoulos P, Archambault L, **Seuntjens J**. Experimental investigation on the accuracy of plastic scintillators and of the spectrum discrimination method in small photon fields. *Med Phys*. 2017 Feb;44(2):654-664. doi: 10.1002/mp.12064. Epub 2017 Feb 6.

### George Shenouda

1. Chatterjee A, Serban M, Abdulkarim B, Panet-Raymond V, Souhami L, **Shenouda G**, Sabri S, Jean-Claude B, Seuntjens J. Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site. *Int J Radiat Oncol Biol Phys*. 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.
2. **Shenouda G**, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot MC, Corredor AG, Abdulkarim B. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by

- Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. *Int J Radiat Oncol Biol Phys*. 2017 Mar 1;97(3):487-494. doi: 10.1016/j.ijrobp.2016.11.006. Epub 2016 Nov 15.
3. Siu LL, Waldron JN, Chen BE, Winkquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, **Shenouda G**, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. *JAMA Oncol*. 2016 Dec 8. doi: 10.1001/jamaoncol.2016.4510. [Epub ahead of print]
  4. Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Kanski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, **Shenouda G**, Matthiesen C, Le QT, Bruner D. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. *Int J Radiat Oncol Biol Phys*. 2017 Mar 15;97(4):687-699. doi: 10.1016/j.ijrobp.2016.08.003. Epub 2016 Aug 12.

### Chaim Shustik

1. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, **Shustik C**, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. *Leukemia*. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.
2. Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, **Shustik C**, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Br J Haematol*. 2017 Aug;178(4):571-582. doi: 10.1111/bjh.14733. Epub 2017 May 9.
3. **Shustik C**, Bence-Bruckler I, Delage R, Owen CJ, Toze CL, Coutre S. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. *Ann Hematol*. 2017 Jul;96(7):1185-1196. doi: 10.1007/s00277-017-2982-1. Epub 2017 Apr 7. Review.
4. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; **IRIS Investigators**. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. *N Engl J Med*. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
5. Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; **iNOVATE Study Group** and the European Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory



Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. *Lancet Oncol.* 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.

### Shireen Sirhan

1. Gupta V, Mesa RA, Deininger MW, Rivera CE, **Sirhan S**, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. *Haematologica.* 2017 Jan;102(1):94-102. doi: 10.3324/haematol.2016.148924. Epub 2016 Sep 15.

### Sonia Skamene

1. **Skamene S**, Agarwal I, Makar M, Krishnan M, Spektor A, Hertan L, Mouw KW, Taylor A, Noveroske Philbrick S, Balboni T. Impact of a dedicated palliative radiation oncology service on the use of single fraction and hypofractionated radiation therapy among patients with bone metastases. *Ann Palliat Med.* 2017 Nov 30. pii: apm.2017.11.02. doi: 10.21037/apm.2017.11.02. [Epub ahead of print]
2. Shi DD, Chen YH, Lam TC, Leonard D, Balboni TA, Schoenfeld A, **Skamene S**, Cagney DN, Chi JH, Cho CH, Harris M, Ferrone ML, Hertan LM. Assessing the utility of a prognostication model to predict 1-year mortality in patients undergoing radiation therapy for spinal metastases. *Spine J.* 2017 Oct 12. pii: S1529-9430(17)31054-9. doi: 10.1016/j.spinee.2017.10.005. [Epub ahead of print]

### Luis Souhami

1. Nichols RC, Hu C, Bahary JP, Zeitzer KL, **Souhami L**, Leibenhaut MH, Rotman M, Gore EM, Balogh AG, McGowan D, Michalski J, Raben A, Rudoler S, Jones CU, Sandler H. Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408. *Adv Radiat Oncol.* 2017 Aug 3;2(4):608-614. doi: 10.1016/j.adro.2017.07.004. eCollection 2017 Oct-Dec.
2. Moraes FY, Mendez LC, Taunk NK, Raman S, Suh JH, **Souhami L**, Slotman B, Weltman E, Spratt DE, Berlin A, Marta GN. Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. *J Neurooncol.* 2017 Nov 21. doi: 10.1007/s11060-017-2687-2. [Epub ahead of print]
3. Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, **Souhami L**, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. *Int J Radiat Oncol Biol Phys.* 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.
4. Chatterjee A, Serban M, Abdulkarim B, Panet-Raymond V, **Souhami L**, Shenouda G, Sabri S, Jean-Claude B, Seuntjens J. Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site. *Int J Radiat Oncol Biol Phys.* 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.
5. Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Garden AS, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon

- JP, Blanchard P; **MARCH Collaborative Group**. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. *Lancet Oncol*. 2017 Sep;18(9):1221-1237. doi: 10.1016/S1470-2045(17)30458-8. Epub 2017 Jul 27.
6. Bachir BG, **Souhami L**, Mansure JJ, Cury F, Vanhuyse M, Brimo F, Aprikian AG, Tanguay S, Sturgeon J, Kassouf W. Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. *Bladder Cancer*. 2017 Apr 27;3(2):105-112. doi: 10.3233/BLC-160090.
  7. Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, **Souhami L**, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, Kinzler K, Jenkins RB, Bettegowda C. Genetic landscape of extreme responders with anaplastic oligodendroglioma. *Oncotarget*. 2017 May 30;8(22):35523-35531. doi: 10.18632/oncotarget.16773.
  8. Azoulay M, Santos F, Shenouda G, Petrecca K, Oweida A, Guiot MC, Owen S, Panet-Raymond V, **Souhami L**, Abdulkarim BS. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution. *J Neurooncol*. 2017 May;132(3):419-426. doi: 10.1007/s11060-017-2383-2. Epub 2017 Apr 3.
  9. Michaelson MD, Hu C, Pham HT, Dahl DM, Lee-Wu C, Swanson GP, Vuky J, Lee RJ, **Souhami L**, Chang B, George A, Sandler H, Shipley W. A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524). *Int J Radiat Oncol Biol Phys*. 2017 Apr 1;97(5):995-1001. doi: 10.1016/j.ijrobp.2016.12.018. Epub 2016 Dec 19.
  10. Turgeon GA, **Souhami L**, Kopek N, Hirsh V, Ofiara L, Faria SL. Thoracic irradiation in 3weeks for limited-stage small cell lung cancer: Is twice a day fractionation really needed? *Cancer Radiother*. 2017 Apr;21(2):89-98. doi: 10.1016/j.canrad.2016.09.015. Epub 2017 Mar 18. Review.
  11. Faria S, Ruo R, Cury F, Duclos M, **Souhami L**. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. *Pract Radiat Oncol*. 2017 Jul - Aug;7(4):264-269. doi: 10.1016/j.pro.2017.01.003. Epub 2017 Jan 20.
  12. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, **Souhami L**, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. *N Engl J Med*. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529.
  13. Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, **Souhami L**, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. *JAMA Oncol*. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.

#### **Alan Spatz**

1. Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, **Spatz A**, Miller

WH Jr. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. *J Immunother Cancer*. 2017 Nov 21;5(1):83. doi: 10.1186/s40425-017-0290-x.

### **Barry Stein**

1. Lee L, Mata J, Droeser RA, Kaneva P, Liberman S, Charlebois P, **Stein B**, Fried GM, Feldman LS. Incisional Hernia After Midline Versus Transverse Specimen Extraction Incision: A Randomized Trial in Patients Undergoing Laparoscopic Colectomy. *Ann Surg*. 2017 Nov 21. doi: 10.1097/SLA.0000000000002615. [Epub ahead of print]
2. Pecorelli N, Fiore JF Jr, Kaneva P, Somasundram A, Charlebois P, Liberman AS, **Stein BL**, Carli F, Feldman LS. An app for patient education and self-audit within an enhanced recovery program for bowel surgery: a pilot study assessing validity and usability. *Surg Endosc*. 2017 Nov 2. doi: 10.1007/s00464-017-5920-3. [Epub ahead of print]
3. Mata J, Fiore JF Jr, Pecorelli N, **Stein BL**, Liberman S, Charlebois P, Feldman LS. Predictors of adherence to enhanced recovery pathway elements after laparoscopic colorectal surgery. *Surg Endosc*. 2017 Sep 15. doi: 10.1007/s00464-017-5865-6. [Epub ahead of print]
4. Gómez-Izquierdo JC, Trainito A, Mirzakandov D, **Stein BL**, Liberman S, Charlebois P, Pecorelli N, Feldman LS, Carli F, Baldini G. Goal-directed Fluid Therapy Does Not Reduce Primary Postoperative Ileus after Elective Laparoscopic Colorectal Surgery: A Randomized Controlled Trial. *Anesthesiology*. 2017 Jul;127(1):36-49. doi: 10.1097/ALN.0000000000001663.
5. Fiore JF Jr, Castelino T, Pecorelli N, Niculiseanu P, Balvardi S, Hershorn O, Liberman S, Charlebois P, **Stein B**, Carli F, Mayo NE, Feldman LS. Ensuring Early Mobilization Within an Enhanced Recovery Program for Colorectal Surgery: A Randomized Controlled Trial. *Ann Surg*. 2017 Aug;266(2):223-231. doi: 10.1097/SLA.0000000000002114.
6. Pecorelli N, Hershorn O, Baldini G, Fiore JF Jr, **Stein BL**, Liberman AS, Charlebois P, Carli F, Feldman LS. Impact of adherence to care pathway interventions on recovery following bowel resection within an established enhanced recovery program. *Surg Endosc*. 2017 Apr;31(4):1760-1771. doi: 10.1007/s00464-016-5169-2. Epub 2016 Aug 18.

### **Khalil Sultanem**

1. Vallières M, Kay-Rivest E, Perrin LJ, Liem X, Furstoss C, Aerts HJWL, Khaouam N, Nguyen-Tan PF, Wang CS, **Sultanem K**, Seuntjens J, El Naqa I. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. *Sci Rep*. 2017 Aug 31;7(1):10117. doi: 10.1038/s41598-017-10371-5.
2. Nair JR, DeBlois F, Ong T, Devic S, Tomic N, Bekerat H, Rosenbloom L, **Sultanem K**, Forghani R. Dual-Energy CT: Balance Between Iodine Attenuation and Artifact Reduction for the Evaluation of Head and Neck Cancer. *J Comput Assist Tomogr*. 2017 Nov/Dec;41(6):931-936. doi: 10.1097/RCT.0000000000000617.

### **Ivan Topisirovic**

1. Guan BJ, van Hoef V, Jobava R, Elroy-Stein O, Valasek LS, Cargnello M, Gao XH, Krokowski D, Merrick WC, Kimball SR, Komar AA, Koromilas AE, Wynshaw-Boris A, **Topisirovic I**, Larsson O, Hatzoglou M. A Unique ISR Program Determines Cellular Responses to Chronic Stress. *Mol Cell*. 2017 Dec 7;68(5):885-900.e6. doi: 10.1016/j.molcel.2017.11.007.

2. Lindqvist LM, Tandoc K, **Topisirovic I**, Furic L. Cross-talk between protein synthesis, energy metabolism and autophagy in cancer. *Curr Opin Genet Dev.* 2017 Nov 24;48:104-111. doi: 10.1016/j.gde.2017.11.003. [Epub ahead of print] Review.
3. Leibovitch M, **Topisirovic I**. Dysregulation of mRNA translation and energy metabolism in cancer. *Adv Biol Regul.* 2017 Nov 2. pii: S2212-4926(17)30170-7. doi: 10.1016/j.jbior.2017.11.001. [Epub ahead of print] Review.
4. Zhan Y, Guo J, Yang W, Goncalves C, Rzymiski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, **Topisirovic I**, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. *J Clin Invest.* 2017 Nov 1;127(11):4179-4192. doi: 10.1172/JCI91258. Epub 2017 Oct 16.
5. Tang L, Morris J, Wan J, Moore C, Fujita Y, Gillaspie S, Aube E, Nanda J, Marques M, Jangal M, Anderson A, Cox C, Hiraishi H, Dong L, Saito H, Singh CR, Witcher M, **Topisirovic I**, Qian SB, Asano K. Competition between translation initiation factor eIF5 and its mimic protein 5MP determines non-AUG initiation rate genome-wide. *Nucleic Acids Res.* 2017 Nov 16;45(20):11941-11953. doi: 10.1093/nar/gkx808.
6. Ramón Y Cajal S, Capdevila C, Hernandez-Losa J, De Mattos-Arruda L, Ghosh A, Lorent J, Larsson O, Aasen T, Postovit LM, **Topisirovic I**. Cancer as an ecomolecular disease and a neoplastic consortium. *Biochim Biophys Acta.* 2017 Dec;1868(2):484-499. doi: 10.1016/j.bbcan.2017.09.004. Epub 2017 Sep 23. Review.
7. Morita M, Prudent J, Basu K, Goyon V, Katsumura S, Hulea L, Pearl D, Siddiqui N, Strack S, McGuirk S, St-Pierre J, Larsson O, **Topisirovic I**, Vali H, McBride HM, Bergeron JJ, Sonenberg N. mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1. *Mol Cell.* 2017 Sep 21;67(6):922-935.e5. doi: 10.1016/j.molcel.2017.08.013. Epub 2017 Sep 14.
8. M Gagné L, Boulay K, **Topisirovic I**, Huot MÉ, Mallette FA. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. *Trends Cell Biol.* 2017 Oct;27(10):738-752. doi: 10.1016/j.tcb.2017.06.002. Epub 2017 Jul 12. Review.
9. Masvidal L, Hulea L, Furic L, **Topisirovic I**, Larsson O. mTOR-sensitive translation: Cleared fog reveals more trees. *RNA Biol.* 2017 Oct 3;14(10):1299-1305. doi: 10.1080/15476286.2017.1290041. Epub 2017 Feb 10.

#### **Anna Towers**

1. Shallwani SM, Hodgson P, **Towers A**. Comparisons Between Cancer-Related and Noncancer-Related Lymphedema: An Overview of New Patients Referred to a Specialized Hospital-Based Center in Canada. *Lymphat Res Biol.* 2017 Mar;15(1):64-69. doi: 10.1089/lrb.2016.0023. Epub 2017 Jan 30.

#### **Michel Tremblay**

1. Penafuerte C, Perez-Quintero LA, Vinette V, Hatzihristidis T, **Tremblay ML**. Mining the Complex Family of Protein Tyrosine Phosphatases for Checkpoint Regulators in Immunity. *Curr Top Microbiol Immunol.* 2017;410:191-214. doi: 10.1007/82\_2017\_68.
2. Penafuerte C, Feldhammer M, Mills JR, Vinette V, Pike KA, Hall A, Migon E, Karsenty G, Pelletier J, Zogopoulos G, **Tremblay ML**. Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFN $\gamma$  signaling.

- Oncoimmunology. 2017 Apr 28;6(6):e1321185. doi: 10.1080/2162402X.2017.1321185. eCollection 2017.
3. Uetani N, Hardy S, Gravel SP, Kiessling S, Pietrobon A, Wong NN, Chénard V, Cermakian N, St-Pierre J, **Tremblay ML**. PRL2 links magnesium flux and sex-dependent circadian metabolic rhythms. *JCI Insight*. 2017 Jul 6;2(13). pii: 91722. doi: 10.1172/jci.insight.91722. [Epub ahead of print]
  4. Ohtake Y, Kong W, Hussain R, Horiuchi M, **Tremblay ML**, Ganea D, Li S. Protein tyrosine phosphatase  $\sigma$  regulates autoimmune encephalomyelitis development. *Brain Behav Immun*. 2017 Oct;65:111-124. doi: 10.1016/j.bbi.2017.05.018. Epub 2017 May 27.
  5. Wu CL, Hardy S, Aubry I, Landry M, Haggarty A, Saragovi HU, **Tremblay ML**. Identification of function-regulating antibodies targeting the receptor protein tyrosine phosphatase sigma ectodomain. *PLoS One*. 2017 May 30;12(5):e0178489. doi: 10.1371/journal.pone.0178489. eCollection 2017.
  6. Bussièrès-Marmen S, Vinette V, Gungabeesoon J, Aubry I, Pérez-Quintero LA, **Tremblay ML**. Loss of T-cell protein tyrosine phosphatase in the intestinal epithelium promotes local inflammation by increasing colonic stem cell proliferation. *Cell Mol Immunol*. 2017 Mar 13. doi: 10.1038/cmi.2016.72. [Epub ahead of print]
  7. Giménez-Mascarell P, Oyénarte I, Hardy S, Breiderhoff T, Stuver M, Kostantin E, Diercks T, Pey AL, Ereño-Orbea J, Martínez-Chantar ML, Khalaf-Nazzal R, Claverie-Martin F, Müller D, **Tremblay ML**, Martínez-Cruz LA. Structural Basis of the Oncogenic Interaction of Phosphatase PRL-1 with the Magnesium Transporter CNNM2. *J Biol Chem*. 2017 Jan 20;292(3):786-801. doi: 10.1074/jbc.M116.759944. Epub 2016 Nov 29.
  8. Johns N, Stretch C, Tan BH, Solheim TS, Sørhaug S, Stephens NA, Gioulbasanis I, Skipworth RJ, Deans DA, Viganò A, Ross JA, Bathe OF, **Tremblay ML**, Kaasa S, Strasser F, Gagnon B, Baracos VE, Damaraju S, Fearon KC. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. *J Cachexia Sarcopenia Muscle*. 2017 Feb;8(1):122-130. doi: 10.1002/jcsm.12138. Epub 2016 Aug 5

### Josie Ursini-Siegel

1. Dannenfelser R, Nome M, Tahiri A, **Ursini-Siegel J**, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG. Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. *Oncotarget*. 2017 Jul 7;8(34):57121-57133. doi: 10.18632/oncotarget.19078. eCollection 2017 Aug 22.
2. Ahn R, Sabourin V, Bolt AM, Hébert S, Totten S, De Jay N, Festa MC, Young YK, Im YK, Pawson T, Koromilas AE, Muller WJ, Mann KK, Kleinman CL, **Ursini-Siegel J**. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. *Nat Commun*. 2017 Mar 9;8:14638. doi: 10.1038/ncomms14638.

### Marie Vanhuyse

1. Hu J, Aprikian AG, Cury FL, **Vanhuyse M**, Zakaria AS, Richard PO, Perreault S, Dragomir A. Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer. *Clin Genitourin Cancer*. 2017 Sep 5. pii: S1558-7673(17)30266-5. doi: 10.1016/j.clgc.2017.08.011. [Epub ahead of print]

2. Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, **Vanhuysse M**, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaad S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH. Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). *J Cancer Educ.* 2017 Aug 4. doi: 10.1007/s13187-017-1259-7. [Epub ahead of print]
3. Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuysse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; **TAXYENERGY Investigators**. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. *J Clin Oncol.* 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. Epub 2017 Jun 20.
4. Bachir BG, Souhami L, Mansure JJ, Cury F, **Vanhuysse M**, Brimo F, Aprikian AG, Tanguay S, Sturgeon J, Kassouf W. Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. *Bladder Cancer.* 2017 Apr 27;3(2):105-112. doi: 10.3233/BLC-160090.
5. Lalani AA, Li H, Heng DY, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, **Vanhuysse M**, Czaykowski P, Reaume MN, Soulières D, Venner P, North S, Basappa NS. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. *Can Urol Assoc J.* 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398.
6. Rocha J, Aprikian AG, **Vanhuysse M**, Cury FL, Hu J, Prévost N, Dragomir A. Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. *CMAJ Open.* 2017 Mar 28;5(1):E265-E272. doi: 10.9778/cmajo.20160082. eCollection 2017 Jan-Mar.
7. Laflamme P, Doucet C, Sirois C, Kopek N, **Vanhuysse M**. Stereotactic radiation therapy for residual chemorefractory primary mediastinal non-seminomatous germ cell tumor after surgical thoracotomy. *Pract Radiat Oncol.* 2017 Jul - Aug;7(4):260-263. doi: 10.1016/j.prro.2017.01.004. Epub 2017 Jan 7. No abstract available.

#### **Tsafir Vanounou**

1. Conlon KC, de Rooij T, van Hilst J, Abu Hidal M, Fleshman J, Talamonti M, **Vanounou T**, Garfinkle R, Velanovich V, Kooby D, Vollmer CM; Minimally Invasive Pancreatic Resection Organizing Committee. Minimally invasive pancreatic resections: cost and value perspectives. *HPB (Oxford).* 2017 Mar;19(3):225-233. doi: 10.1016/j.hpb.2017.01.019. Epub 2017 Mar 6.

#### **Carol-Ann Vasilevsky**

1. Garfinkle R, Abou-Khalil J, Morin N, Ghitulescu G, **Vasilevsky CA**, Gordon P, Demian M, Boutros M. Is There a Role for Oral Antibiotic Preparation Alone Before Colorectal Surgery? ACS-NSQIP Analysis by Coarsened Exact Matching. *Dis Colon Rectum.* 2017 Jul;60(7):729-737. doi: 10.1097/DCR.0000000000000851.

2. Fung A, Trabulsi N, Morris M, Garfinkle R, Saleem A, Wexner SD, **Vasilevsky CA**, Boutros M. Laparoscopic colorectal cancer resections in the obese: a systematic review. *Surg Endosc*. 2017 May;31(5):2072-2088. doi: 10.1007/s00464-016-5209-y. Epub 2016 Oct 24.

### **Antonio Vigano**

1. **Vigano A**, Kasvis P, Di Tomasso J, Gillis C, Kilgour R, Carli F. Pearls of optimizing nutrition and physical performance of older adults undergoing cancer therapy. *J Geriatr Oncol*. 2017 Nov;8(6):428-436. doi: 10.1016/j.jgo.2017.08.013. Epub 2017 Sep 22.
2. Johns N, Stretch C, Tan BH, Solheim TS, Sørhaug S, Stephens NA, Gioulbasanis I, Skipworth RJ, Deans DA, **Vigano A**, Ross JA, Bathe OF, Tremblay ML, Kaasa S, Strasser F, Gagnon B, Baracos VE, Damaraju S, Fearon KC. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. *J Cachexia Sarcopenia Muscle*. 2017 Feb;8(1):122-130. doi: 10.1002/jcsm.12138. Epub 2016 Aug 5.
3. **Vigano AAL**, Morais JA, Ciutto L, Rosenthal L, di Tomasso J, Khan S, Olders H, Borod M, Kilgour RD. Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients. *Clin Nutr*. 2017 Oct;36(5):1378-1390. doi: 10.1016/j.clnu.2016.09.008. Epub 2016 Sep 20.
4. Lerner L, Tao J, Liu Q, Nicoletti R, Feng B, Krieger B, Mazsa E, Siddiquee Z, Wang R, Huang L, Shen L, Lin J, **Vigano A**, Chiu MI, Weng Z, Winston W, Weiler S, Gyuris J. MAP3K11/GDF15 axis is a critical driver of cancer cachexia. *J Cachexia Sarcopenia Muscle*. 2016 Sep;7(4):467-82. doi: 10.1002/jcsm.12077. Epub 2015 Oct 29.
5. Aapro M, Scotte F, Bouillet T, Currow D, **Vigano A**. A Practical Approach to Fatigue Management in Colorectal Cancer. *Clin Colorectal Cancer*. 2017 Dec;16(4):275-285. doi: 10.1016/j.clcc.2016.04.010. Epub 2016 May 7. Review.

### **Té Vuong**

1. Liang LH, Tomic N, **Vuong T**, Aldelaijan S, Bekerat H, DeBlois F, Seuntjens J, Devic S. Physics aspects of the Papillon technique-Five decades later. *Brachytherapy*. 2017 Nov 1. pii: S1538-4721(17)30474-9. doi: 10.1016/j.brachy.2017.09.016. [Epub ahead of print]
2. Siddiqui MRS, Simillis C, Hunter C, Chand M, Bhoday J, Garant A, **Vuong T**, Artho G, Rasheed S, Tekkis P, Abulafi AM, Brown G. A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. *Br J Cancer*. 2017 Jun 6;116(12):1513-1519. doi: 10.1038/bjc.2017.99. Epub 2017 Apr 27. Review.

### **Scott Weichenthal**

1. **Weichenthal S**, Pinault LL, Burnett RT. Impact of Oxidant Gases on the Relationship between Outdoor Fine Particulate Air Pollution and Nonaccidental, Cardiovascular, and Respiratory Mortality. *Sci Rep*. 2017 Nov 27;7(1):16401. doi: 10.1038/s41598-017-16770-y.
2. Villeneuve PJ, Jerrett M, Su JG, **Weichenthal S**, Sandler DP. Association of residential greenness with obesity and physical activity in a US cohort of women. *Environ Res*. 2018 Jan;160:372-384. doi: 10.1016/j.envres.2017.10.005. Epub 2017 Oct 20.
3. **Weichenthal S**, Baumgartner J, Hanley JA. Sample Size Estimation for Random-effects Models: Balancing Precision and Feasibility in Panel Studies. *Epidemiology*. 2017 Nov;28(6):817-826. doi: 10.1097/EDE.0000000000000727.

4. **GBD 2016 Risk Factors Collaborators.** Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1345-1422. doi: 10.1016/S0140-6736(17)32366-8.
5. **GBD 2016 DALYs and HALE Collaborators.** Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1260-1344. doi: 10.1016/S0140-6736(17)32130-X.
6. **GBD 2016 Disease and Injury Incidence and Prevalence Collaborators.** Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2.
7. **GBD 2016 Mortality Collaborators.** Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1084-1150. doi: 10.1016/S0140-6736(17)31833-0.
8. **GBD 2016 SDG Collaborators.** Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. *Lancet.* 2017 Sep 16;390(10100):1423-1459. doi: 10.1016/S0140-6736(17)32336-X. Epub 2017 Sep 12.
9. Pinault LL, **Weichenthal S**, Crouse DL, Brauer M, Erickson A, Donkelaar AV, Martin RV, Hystad P, Chen H, Finès P, Brook JR, Tjepkema M, Burnett RT. Associations between fine particulate matter and mortality in the 2001 Canadian Census Health and Environment Cohort. *Environ Res.* 2017 Nov;159:406-415. doi: 10.1016/j.envres.2017.08.037. Epub 2017 Sep 18.
10. **Weichenthal S**, Bai L, Hatzopoulou M, Van Ryswyk K, Kwong JC, Jerrett M, van Donkelaar A, Martin RV, Burnett RT, Lu H, Chen H. Long-term exposure to ambient ultrafine particles and respiratory disease incidence in Toronto, Canada: a cohort study. *Environ Health.* 2017 Jun 19;16(1):64. doi: 10.1186/s12940-017-0276-7.
11. Stieb DM, Shutt R, Kauri L, Mason S, Chen L, Szyszkowicz M, Dobbin NA, Rigden M, Jovic B, Mulholland M, Green MS, Liu L, Pelletier G, **Weichenthal SA**, Dales RE, Luginaah I. Cardio-Respiratory Effects of Air Pollution in a Panel Study of Outdoor Physical Activity and Health in Rural Older Adults. *J Occup Environ Med.* 2017 Apr;59(4):356-364. doi: 10.1097/JOM.0000000000000954.
12. Goldberg MS, Labrèche F, **Weichenthal S**, Lavigne E, Valois MF, Hatzopoulou M, Van Ryswyk K, Shekarrizfard M, Villeneuve PJ, Crouse D, Parent MÉ. The association between the incidence of postmenopausal breast cancer and concentrations at street-level of nitrogen dioxide and ultrafine particles. *Environ Res.* 2017 Oct;158:7-15. doi: 10.1016/j.envres.2017.05.038. Epub 2017 Jun 5.
13. Van Ryswyk K, Anastasopoulos AT, Evans G, Sun L, Sabaliauskas K, Kulka R, Wallace L, **Weichenthal S**. Metro Commuter Exposures to Particulate Air Pollution and PM2.5-Associated Elements in Three Canadian Cities: The Urban Transportation Exposure Study. *Environ Sci Technol.* 2017 May 16;51(10):5713-5720. doi: 10.1021/acs.est.6b05775. Epub 2017 Apr 25.



14. **Weichenthal S**, Lavigne E, Valois MF, Hatzopoulou M, Van Ryswyk K, Shekarrizfard M, Villeneuve PJ, Goldberg MS, Parent ME. Spatial variations in ambient ultrafine particle concentrations and the risk of incident prostate cancer: A case-control study. *Environ Res.* 2017 Jul;156:374-380. doi: 10.1016/j.envres.2017.03.035. Epub 2017 Apr 10.
15. **Weichenthal S**, Kulka R, Lavigne E, van Rijswijk D, Brauer M, Villeneuve PJ, Stieb D, Joseph L, Burnett RT. Biomass Burning as a Source of Ambient Fine Particulate Air Pollution and Acute Myocardial Infarction. *Epidemiology.* 2017 May;28(3):329-337. doi: 10.1097/EDE.0000000000000636.
16. Shutt RH, Kauri LM, **Weichenthal S**, Kumarathasan P, Vincent R, Thomson EM, Liu L, Mahmud M, Cakmak S, Dales R. Exposure to air pollution near a steel plant is associated with reduced heart rate variability: a randomised crossover study. *Environ Health.* 2017 Jan 28;16(1):4. doi: 10.1186/s12940-016-0206-0.
17. Lavigne É, Bélair MA, Do MT, Stieb DM, Hystad P, van Donkelaar A, Martin RV, Crouse DL, Crighton E, Chen H, Brook JR, Burnett RT, **Weichenthal S**, Villeneuve PJ, To T, Cakmak S, Johnson M, Yasseen AS 3rd, Johnson KC, Ofner M, Xie L, Walker M. Maternal exposure to ambient air pollution and risk of early childhood cancers: A population-based study in Ontario, Canada. *Environ Int.* 2017 Mar;100:139-147. doi: 10.1016/j.envint.2017.01.004. Epub 2017 Jan 17.
18. Hong KY, **Weichenthal S**, Saraswat A, King GH, Henderson SB, Brauer M. Systematic identification and prioritization of communities impacted by residential woodsmoke in British Columbia, Canada. *Environ Pollut.* 2017 Jan;220(Pt B):797-806. doi: 10.1016/j.envpol.2016.10.056. Epub 2016 Nov 9.
19. Lavigne E, Gasparrini A, Stieb DM, Chen H, Yasseen AS 3rd, Crighton E, To T, **Weichenthal S**, Villeneuve PJ, Cakmak S, Coates F, Walker M. Maternal Exposure to Aeroallergens and the Risk of Early Delivery. *Epidemiology.* 2017 Jan;28(1):107-115.

### **Michael Witcher**

1. Tang L, Morris J, Wan J, Moore C, Fujita Y, Gillaspie S, Aube E, Nanda J, Marques M, Jangal M, Anderson A, Cox C, Hiraishi H, Dong L, Saito H, Singh CR, **Witcher M**, Topisirovic I, Qian SB, Asano K. Competition between translation initiation factor eIF5 and its mimic protein 5MP determines non-AUG initiation rate genome-wide. *Nucleic Acids Res.* 2017 Nov 16;45(20):11941-11953. doi: 10.1093/nar/gkx808.
2. Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, Richard S, Alaoui-Jamali M, Orthwein A, McCaffrey L, **Witcher M**. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. *Sci Adv.* 2017 May 24;3(5):e1601898. doi: 10.1126/sciadv.1601898. eCollection 2017 May.

### **Jian-Hui Wu**

1. Sze A, Olagnier D, Hadj SB, Han X, Tian XH, Xu HT, Yang L, Shi Q, Wang P, Wainberg MA, **Wu JH**, Lin R. Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference. *Viruses.* 2017 Oct 3;9(10). pii: E287. doi: 10.3390/v9100287.
2. Deng J, Li Y, Pennati A, Yuan S, **Wu JH**, Waller EK, Galipeau J. GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration. *Mol Ther.* 2017 Feb 1;25(2):416-426. doi: 10.1016/j.ymthe.2016.11.013.

**Norma Ybarra**

1. Perez JR, **Ybarra N**, Chagnon F, Serban M, Pare G, Lesur O, Seuntjens J, Naqa IE. Image-Guided Fluorescence Endomicroscopy: From Macro- to Micro-Imaging of Radiation-Induced Pulmonary Fibrosis. *Sci Rep.* 2017 Dec 19;7(1):17829. doi: 10.1038/s41598-017-18070-x.
2. Perez JR, Lee S, **Ybarra N**, Maria O, Serban M, Jeyaseelan K, Wang LM, Seuntjens J, Naqa IE. A comparative analysis of longitudinal computed tomography and histopathology for evaluating the potential of mesenchymal stem cells in mitigating radiation-induced pulmonary fibrosis. *Sci Rep.* 2017 Aug 22;7(1):9056. doi: 10.1038/s41598-017-09021-7.
3. Perez JR, **Ybarra N**, Chagnon F, Serban M, Lee S, Seuntjens J, Lesur O, El Naqa I. Tracking of Mesenchymal Stem Cells with Fluorescence Endomicroscopy Imaging in Radiotherapy-Induced Lung Injury. *Sci Rep.* 2017 Jan 19;7:40748. doi: 10.1038/srep40748.